<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.0 20040830//EN" "journalpublishing.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="2.0" xml:lang="en" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">JMIR Cancer</journal-id><journal-id journal-id-type="publisher-id">cancer</journal-id><journal-id journal-id-type="index">21</journal-id><journal-title>JMIR Cancer</journal-title><abbrev-journal-title>JMIR Cancer</abbrev-journal-title><issn pub-type="epub">2369-1999</issn><publisher><publisher-name>JMIR Publications</publisher-name><publisher-loc>Toronto, Canada</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">v12i1e78797</article-id><article-id pub-id-type="doi">10.2196/78797</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Using Latent Dirichlet Allocation Topic Modeling to Uncover Latent Research Topics and Trends in Renal Cell Carcinoma: Bibliometric Review</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>De La Hoz-M</surname><given-names>Javier</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Montes-Escobar</surname><given-names>Karime</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Salas-Macias</surname><given-names>Carlos Alfredo</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Fors</surname><given-names>Martha</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ballaz</surname><given-names>Santiago J</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff6">6</xref></contrib></contrib-group><aff id="aff1"><institution>Universidad del Magdalena</institution><addr-line>Santa Marta</addr-line><country>Colombia</country></aff><aff id="aff2"><institution>Departamento de Ciencias Agr&#x00ED;colas, Facultad de Ingenier&#x00ED;a Agr&#x00ED;cola, Universidad T&#x00E9;cnica de Manab&#x00ED;</institution><addr-line>Portoviejo</addr-line><country>Ecuador</country></aff><aff id="aff3"><institution>Departamento de Formaci&#x00F3;n y Desarrollo Cient&#x00ED;fico en Ingenier&#x00ED;a, Facultad de Ingenier&#x00ED;a, Ciencia y Tecnolog&#x00ED;a, Universidad Bernardo O&#x2019;Higgins</institution><addr-line>Santiago de Chile</addr-line><country>Chile</country></aff><aff id="aff4"><institution>Laboratory of Agroecosystems Functioning and Climate Change &#x2013; FAGROCLIM, Departamento de Ciencias Agron&#x00F3;micas, Facultad de Ingenier&#x00ED;as Agroambientales, Universidad T&#x00E9;cnica de Manab&#x00ED;</institution><addr-line>Santa Ana</addr-line><country>Ecuador</country></aff><aff id="aff5"><institution>Facultad de Ciencias de la Salud, Escuela de Medicina, Universidad de Las Am&#x00E9;ricas</institution><addr-line>Granados v&#x00ED;a a Nay&#x00F3;n sin n&#x00FA;mero</addr-line><addr-line>Quito</addr-line><country>Ecuador</country></aff><aff id="aff6"><institution>Facultad de Ciencias de la Salud &#x201C;Dr. Enrique Ortega Moreira&#x201D;, Universidad Esp&#x00ED;ritu Santo</institution><addr-line>Samborond&#x00F3;n</addr-line><country>Ecuador</country></aff><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Cahill</surname><given-names>Naomi</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name name-style="western"><surname>Fan</surname><given-names>G</given-names></name></contrib><contrib contrib-type="reviewer"><name name-style="western"><surname>Raymond Guo</surname><given-names>L</given-names></name></contrib><contrib contrib-type="reviewer"><name name-style="western"><surname>Bievre</surname><given-names>Nicolas</given-names></name></contrib></contrib-group><author-notes><corresp>Correspondence to Martha Fors, MD, PhD, Facultad de Ciencias de la Salud, Escuela de Medicina, Universidad de Las Am&#x00E9;ricas, Granados v&#x00ED;a a Nay&#x00F3;n sin n&#x00FA;mero, Quito, 177022, Ecuador, 593 95016627; <email>martha.fors@udla.edu.ec</email></corresp></author-notes><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>16</day><month>1</month><year>2026</year></pub-date><volume>12</volume><elocation-id>e78797</elocation-id><history><date date-type="received"><day>10</day><month>06</month><year>2025</year></date><date date-type="rev-recd"><day>31</day><month>10</month><year>2025</year></date><date date-type="accepted"><day>31</day><month>10</month><year>2025</year></date></history><copyright-statement>&#x00A9; Javier De La Hoz-M, Karime Montes-Escobar, Carlos Alfredo Salas-Macias, Martha Fors, Santiago J Ballaz. Originally published in JMIR Cancer (<ext-link ext-link-type="uri" xlink:href="https://cancer.jmir.org">https://cancer.jmir.org</ext-link>), 16.1.2026. </copyright-statement><copyright-year>2026</copyright-year><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Cancer, is properly cited. The complete bibliographic information, a link to the original publication on <ext-link ext-link-type="uri" xlink:href="https://cancer.jmir.org/">https://cancer.jmir.org/</ext-link>, as well as this copyright and license information must be included.</p></license><self-uri xlink:type="simple" xlink:href="https://cancer.jmir.org/2026/1/e78797"/><abstract><sec><title>Background</title><p>Renal cell carcinoma (RCC) is a common, often lethal kidney cancer that originates in the renal cortex. Its incidence is rising, and major factors include smoking, obesity, and hypertension, though its etiology is uncertain. While surgery is effective for localized RCC, treatments for metastatic RCC have advanced significantly due to better diagnostic, prognostic, and predictive tools. Despite this progress, challenges remain, including long-term drug resistance and the complexity of RCC as a diverse group of diseases rather than a single entity.</p></sec><sec><title>Objective</title><p>The aim of this bibliometric review was a comprehensive analysis of the topics and trends in RCC research, offering a foundation for future investigations.</p></sec><sec sec-type="methods"><title>Methods</title><p>We used R &#x201C;Bibliometrix&#x201D; to conduct a bibliographic search in Scopus and PubMed covering publications from 1975 to 2023 to statistically assess the distribution of publications associated with RCC by year, journal, and country. Topic modeling of RCC research was conducted using latent Dirichlet allocation, a Bayesian network-based probabilistic algorithm that identifies unobserved thematic clusters in a collection of text documents. Trends in the retrieved themes were then characterized by using regression slopes over time, across countries, and in different journals. These trends were visualized as a heatmap, which was then used for hierarchical clustering to group similar topics based on their correlation strengths.</p></sec><sec sec-type="results"><title>Results</title><p>A total of 35,228 documents from 3070 sources were found, with a steady yearly growth of 9.86% and 118 participating countries. Thirty topics with the best coherence score were found in 8 crucial domains: treatment and therapies, biomolecular and genetic characteristics, disease characteristics and progression, diagnosis and evaluation, metastasis and dissemination, epidemiology and risk factors, related conditions, and pathological features. The pertinent clustergrams that resulted from the heatmaps mirrored the latent Dirichlet allocation&#x2019;s algorithm identification of major RCC research subjects.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>Over 50 years, RCC research&#x2019;s focus has shifted from diagnosis and assessment to a more thorough understanding of disease characteristics and progression. Because many patients are diagnosed with abdominal imaging studies, an emerging topic in RCC is diagnostic imaging and radiological evolution. The advances in omics technologies and the function of microRNA signature in the progression, diagnosis, therapy targeting, and prognosis of RCC have garnered a lot of attention. The discovery of the genetic background has enhanced our understanding of the growth of RCC. Drug resistance, local RCC ablation, and postoperative surveillance of RCC recurrence following nephrectomy are key future research avenues. The next generation of drug-targeted therapy and immunotherapy will make it possible to successfully treat metastatic RCC following nephrectomy. Neglected topics include the association between ferroptosis and RCC, the long-term assessment of novel treatments, and the application of artificial intelligence on RCC. Our bibliographic review delivered pertinent data for clinical decision-making and the planning of future RCC research.</p></sec></abstract><kwd-group><kwd>bibliometrics</kwd><kwd>carcinoma renal cell</kwd><kwd>knowledge discovery</kwd><kwd>machine learning</kwd><kwd>research</kwd></kwd-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Renal cell carcinoma (RCC) is the term coined to describe the malignant transformation of proximal renal tubular epithelium within the renal cortex [<xref ref-type="bibr" rid="ref1">1</xref>]. RCC accounts for approximately 90% of all renal malignancies [<xref ref-type="bibr" rid="ref2">2</xref>] and for approximately 2% of all cancer diagnoses and cancer deaths worldwide [<xref ref-type="bibr" rid="ref3">3</xref>]. With a 2:1 ratio of new diagnoses, men are more likely than women to be affected by RCC, whose incidence rises significantly with age. RCC is a serious health problem since it is often a lethal kidney cancer with an increasing incidence worldwide. Its relevance is also tied to challenges in early diagnosis and the development of aggressive subtypes like those involving tumor thrombus. RCC&#x2019;s etiology is uncertain. The 3 main risk factors for RCC include being overweight, having hypertension, and smoking cigarettes [<xref ref-type="bibr" rid="ref3">3</xref>]. Medical disorders such as chronic kidney disease, hemodialysis, kidney transplantation, polycystic kidney disease, and renal stones are additional risk factors for RCC. Numerous dietary, occupational, environmental, and lifestyle factors have also been linked to the development of RCC [<xref ref-type="bibr" rid="ref4">4</xref>]. Even though the majority of RCCs are sporadic, 3%&#x2010;5% of all RCC diagnoses occur in patients younger than 46 years, which suggests an underlying RCC form that is inherited [<xref ref-type="bibr" rid="ref5">5</xref>].</p><p>In terms of treatment, surgery is a successful strategy for managing localized RCC, but conventional chemotherapy is ineffective for treating metastatic RCC. Thankfully, during the past 10 years, amazing progress has been made in treating metastatic RCC, resulting in a significant drop in the cancer&#x2019;s death rates despite a continuous rise in the number of individuals receiving a diagnosis. The main factor for the improvement in RCC survival over the past few decades has been the wide diagnostic, prognostic, and predictive methodologies that are currently available [<xref ref-type="bibr" rid="ref6">6</xref>,<xref ref-type="bibr" rid="ref7">7</xref>]. Despite these advancements, long-term RCC drug resistance is still a problem [<xref ref-type="bibr" rid="ref8">8</xref>]. While accelerating RCC cures is critically needed, research on RCC faces various obstacles. Prior to the discovery of the <italic>VHL</italic> gene, kidney cancer was regarded as a single disease [<xref ref-type="bibr" rid="ref9">9</xref>]. In fact, kidney cancer is a multitude of diverse diseases, each with its own genetic makeup [<xref ref-type="bibr" rid="ref10">10</xref>]. This has delayed the search for a cure by impeding reproducibility across studies and appropriate interpretation of the research [<xref ref-type="bibr" rid="ref11">11</xref>].</p><p>RCC offers an intricate and challenging research landscape that hinders scientific progress. The goal of this study was to conduct a comprehensive and up-to-date summary of the topic structure, novel research avenues, study trends, and knowledge gaps in RCC research. Conventional bibliometric methods, scientific mappings, and network visualization studies fall short in offering this kind of text analysis [<xref ref-type="bibr" rid="ref12">12</xref>], since they frequently necessitate manual categorization or extensive, subjective human intervention [<xref ref-type="bibr" rid="ref13">13</xref>-<xref ref-type="bibr" rid="ref16">16</xref>]. Instead, we sought a corpus of text-based data for research trends and topics by using a topic algorithm model called latent Dirichlet allocation (LDA) [<xref ref-type="bibr" rid="ref17">17</xref>]. We intended for RCC research documents &#x201C;to tell the story themselves&#x201D; and for topics to emerge on their own, without human intervention, and only based on their statistical characteristics.</p></sec><sec id="s2" sec-type="methods"><title>Methods</title><sec id="s2-1"><title>Search Strategy and Data Collection</title><p>This study was based on data obtained from PubMed [<xref ref-type="bibr" rid="ref18">18</xref>] and Scopus [<xref ref-type="bibr" rid="ref19">19</xref>] as of April 6, 2023. We chose Scopus over other databases because of its superior coverage in the health sciences field, accurate indexing, and &#x201C;federated search interface&#x201D; (ie, functionality), which enables us to query the content found across its sources using a common or standardized search form. The authoritative and comprehensive PubMed is the top choice for searching medical and health sciences literature. Medical Subject Headings (MeSH) terms were used for the PubMed search to improve comprehensiveness. Raw data were stored in <italic>TXT</italic> and <italic>CSV</italic> files, respectively. The R &#x201C;Bibliometrix&#x201D; tool of the R Statistical software [<xref ref-type="bibr" rid="ref20">20</xref>] was used to clean data and integrate the 2 databases&#x2019; unique publications into a combined dataset (with and without assigned DOI) [<xref ref-type="bibr" rid="ref18">18</xref>,<xref ref-type="bibr" rid="ref19">19</xref>,<xref ref-type="bibr" rid="ref21">21</xref>-<xref ref-type="bibr" rid="ref23">23</xref>]. At this point, duplicate documents with an assigned DOI (1809 in total) were eliminated. The inclusion criteria for the outcome were all the research documents, written in English in peer-reviewed journals, that were published between 1974 (the earliest article we found) and 2023, and that dealt with RCC. Books, book chapters, gray literature, and reports were not included to avoid noise. The search strings, which used a Boolean computation, are indicated in <xref ref-type="table" rid="table1">Table 1</xref>. Only those articles with the term &#x201C;renal cell carcinoma&#x201D; in their title or abstract were selected. The leader and the other authors reviewed the complete list of all possible acceptable publications. Their reliability and value to the field were based on criteria like the journal&#x2019;s impact factor, author affiliations, and citation count.</p><table-wrap id="t1" position="float"><label>Table 1.</label><caption><p>Enhanced information retrieval for research on renal cell carcinoma.</p></caption><table id="table1" frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom">Database</td><td align="left" valign="bottom">Search data</td><td align="left" valign="bottom">Search string</td><td align="left" valign="bottom">Results, n</td></tr></thead><tbody><tr><td align="left" valign="top">PubMed</td><td align="left" valign="top">April 6, 2024</td><td align="left" valign="top">&#x201C;renal cell carcinoma&#x201D;[Title/Abstract] AND &#x201C;english&#x201D;[Language] AND &#x201C;journal article&#x201D;[Publication Type] AND 1974/01/01:2023/12/31[Date - Publication]</td><td align="left" valign="top">38,577</td></tr><tr><td align="left" valign="top">Scopus</td><td align="left" valign="top">April 6, 2024</td><td align="left" valign="top">TITLE-ABS ( &#x201C;renal cell carcinoma&#x201D; ) AND PUBYEAR&#x003E;1973 AND PUBYEAR&#x003C;2024 AND ( LIMIT-TO ( DOCTYPE , &#x201C;ar&#x201D; ) OR LIMIT-TO ( DOCTYPE , &#x201C;re&#x201D; ) ) AND ( LIMIT-TO ( SRCTYPE , &#x201C;j&#x201D; ) ) AND ( LIMIT-TO ( LANGUAGE , &#x201C;English&#x201D; ) )</td><td align="left" valign="top">40,479</td></tr></tbody></table></table-wrap></sec><sec id="s2-2"><title>Bibliometrix Analysis</title><p>Our bibliometric review procedure adhered to best practice guidance published elsewhere [<xref ref-type="bibr" rid="ref24">24</xref>] (<xref ref-type="supplementary-material" rid="app1">Checklist 1</xref>). A preliminary descriptive analysis of the retrieved information was carried out using the R package bibliometrix [<xref ref-type="bibr" rid="ref22">22</xref>]. This open-source application analyzes publication and citation metrics using mathematical and statistical methods to obtain a broad picture of the scientific output that was within the purview of the study. The questions answered were as follows: (Q1) What are the primary research topics in RCC? (Q2) How have RCC research questions changed over time? (Q3) How are these research topics distributed across countries and scientific journals? Three levels of analysis&#x2014;countries, sources, and authors&#x2014;were included at this stage to answer the above questions.</p><p>The annual growth rate of publications was calculated using the Bibliometrix package in R, which computes the compound annual growth rate (CAGR) using the following equation:</p><disp-formula id="E1"><label>(1)</label><mml:math id="eqn1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mtext>CAGR</mml:mtext><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mi mathvariant="normal">f</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mi>n</mml:mi></mml:mfrac></mml:mrow></mml:msup><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo></mml:mstyle></mml:mrow></mml:mstyle></mml:math></disp-formula><p>where <italic>V</italic><sub>f</sub> is the number of publications in the final year of the study period, <italic>V</italic><sub>i</sub> is the number of publications in the initial year of the study period, and <italic>n</italic> is the number of years between the initial and final year.</p></sec><sec id="s2-3"><title>Latent Dirichlet Allocation</title><p>The unsupervised machine learning algorithm LDA [<xref ref-type="bibr" rid="ref17">17</xref>] was applied to identify topics. Considered an extension of the probabilistic latent semantic analysis, it has its roots in Bayesian models [<xref ref-type="bibr" rid="ref17">17</xref>,<xref ref-type="bibr" rid="ref25">25</xref>]. Topics in LDA are thought of as multinomial distributions of vocabulary terms, in which each word has a given probability of occurring in a topic. This leads to the prominence of words that are more frequently used in a topic, creating clusters that reflect specific underlying themes. LDA does not require prior knowledge of the topics or the way they are presented in the texts. Rather, topics merely flow from the statistical properties of the data and the model&#x2019;s underlying assumptions. For thematic analysis, it was decided to use abstracts rather than entire texts because topics are more coherent and ranked higher in large document collections. Inaccurate or noisy terms have less impact on topic word distribution [<xref ref-type="bibr" rid="ref26">26</xref>].</p><p>The LDA model was validated using the Cv metric, which is grounded in the distributional hypothesis stating that words with similar meanings tend to coexist in similar contexts [<xref ref-type="bibr" rid="ref27">27</xref>]. In other words, Cv rates the semantic similarity of words within a topic (ie, topic interpretability). The Cv score was calculated by looking at word co-occurrence statistics in a reference corpus and their conformity to human-like semantic interpretation. The package textmineR was used for such analysis, which made it easier to determine the ideal number of topics (<italic>k</italic>) for the study. Because higher scores indicate better interpretability, a model with the highest coherence score among those in the study rank (from <italic>k</italic>=4 to 50) was selected to reach a balance between granularity and thematic clarity.</p></sec><sec id="s2-4"><title>Identifying Research Topics</title><p>The procedure for identifying topics through LDA was divided into 3 stages: (1) preprocessing, (2) construction of the LDA model, and (3) assigning labels to topics. LDAShiny [<xref ref-type="bibr" rid="ref28">28</xref>], an open-source R package that uses Bayesian inference for LDA and machine learning algorithms to improve the analytical process, was selected for the first 2 stages.</p><sec id="s2-4-1"><title>Preprocessing</title><p>Converting all documents into a standardized format for ease of handling was the objective of the stage known as &#x201C;Text refining&#x201D; [<xref ref-type="bibr" rid="ref29">29</xref>]. Initially, textual data consisted solely of character sets. To enhance topic coherence, each abstract underwent tokenization using bigrams, which are consecutive unigram combinations. This process involves converting text to lowercase and removing punctuation marks, dashes, brackets, numbers, spaces, and &#x201C;stop words.&#x201D; The list of stop words was extracted from standard libraries such as Natural Language ToolKit and Snowball and was modified to include unrelated terms unique to the medical and technical domains.</p><p>The preprocessed data result in the creation of a document-term matrix in which each document is represented as a vector containing an unordered collection of words. If the corpus contains a total of V words, each document becomes a V-dimensional vector, with the value of each element representing the frequency of the corresponding word in the document.</p></sec><sec id="s2-4-2"><title>Construction of the LDA Model</title><p>LDA assumes that topics are shared by all documents in the collection, while subject proportions vary stochastically between documents, as they are randomly extracted from a Dirichlet distribution [<xref ref-type="bibr" rid="ref30">30</xref>]. Establishing the expected number of topics was done a priori, making it a nontrivial task to choose the right number of topics (<italic>k</italic>) for a given collection of items. Since the optimal number of topics was unknown beforehand, we generated different models ranging from 4 to 40 topics. We ran 1000 iterations for Gibbs sampling [<xref ref-type="bibr" rid="ref31">31</xref>] and utilized the default values of the LDAShiny package for Dirichlet parameters &#x03B1; and &#x03B2;. We used Cv as the topic coherence measure of the topics generated by LDA models [<xref ref-type="bibr" rid="ref32">32</xref>].</p></sec><sec id="s2-4-3"><title>Assigning Labels to Topics</title><p>The LDA model generates topics without semantic labels. Given that algorithmic analyses are not always able to fully capture the implicit meanings of human language, manual labeling is widely recognized as a normal practice in topic modeling [<xref ref-type="bibr" rid="ref32">32</xref>]. The manual topic labeling involved a diverse team of 7 experts, including the authors and independent scholars with backgrounds in oncology research and bibliometric analysis. Team members were provided with 2 sources of information: the lists of most frequently occurring words (presumably) provided by the model and a sample of 3 document titles with their corresponding summaries classified by the algorithm. They were asked to independently validate and summarize the identified topics and investigate existing literature to identify research trends, gaps, and influential works. Discrepancies between team members were resolved through remote communications to minimize bias, improve rigor, and ensure the theme structures and semantic interpretation were aligned with the research objective. Reference [<xref ref-type="bibr" rid="ref32">32</xref>] provides a guide to the procedures used to ensure the trustworthiness of the labels issued, with the difference that we used up to 16 annotators rating candidate labels.</p><p>By providing the most relevant and thematically aligned examples within each topic, these articles guaranteed readability and clarity. The 2 articles chosen allowed for a concise and efficient summary of each topic&#x2019;s key ideas without overwhelming the analysis and the reader. This approach strikes a balance between realistic representation and practical interpretability. These articles were then condensed into succinct summaries that encapsulated the essence of each topic. This manual approach not only provided a gold-standard reference [<xref ref-type="bibr" rid="ref32">32</xref>] but also ensured interpretability and utility in the context of the study.</p></sec></sec><sec id="s2-5"><title>Quantitative Indices</title><p>For each topic, additional characteristics were revealed, especially at the journal and country levels, through statistical description based on the probability distributions of document-topic and topic-word acquired through LDA. To make results and findings more evident, we used certain quantitative indices suggested by Xiong and colleagues [<xref ref-type="bibr" rid="ref33">33</xref>], which were obtained by adding document-topic and topic-word distributions. The indexes were described as follows.</p><p>The distribution of topics over time was obtained by the following equation:</p><disp-formula id="E2"><label>(2)</label><mml:math id="eqn2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msubsup><mml:mi>&#x03B8;</mml:mi><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>y</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:munder><mml:mo>&#x2211;</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>&#x2208;</mml:mo><mml:mi>y</mml:mi></mml:mrow></mml:munder><mml:msub><mml:mi>&#x03B8;</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msup><mml:mi>n</mml:mi><mml:mrow><mml:mi>y</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo></mml:mstyle></mml:mstyle></mml:mrow></mml:mstyle></mml:math></disp-formula><p>where <italic>m</italic>&#x03F5;<italic>j</italic> represents articles published each year, <italic>&#x03B8;</italic><sub><italic>mk</italic></sub> is the proportion of the <italic>k</italic>th topic in each item, and <italic>n</italic><sup><italic>y</italic></sup> is the total number of articles published in the year.</p><p>Topic distribution across journals was defined as the ratio of the <italic>k</italic>th topic in the journal <italic>j</italic>: <inline-formula><mml:math id="ieqn1"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:msubsup><mml:mi>&#x03B8;</mml:mi><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> as indicated in the following equation:</p><disp-formula id="E3"><label>(3)</label><mml:math id="eqn3"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msubsup><mml:mi>&#x03B8;</mml:mi><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:munder><mml:mo>&#x2211;</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>&#x2208;</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:munder><mml:msub><mml:mi>&#x03B8;</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msup><mml:mi>n</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo></mml:mstyle></mml:mstyle></mml:mrow></mml:mstyle></mml:math></disp-formula><p>where <italic>m</italic>&#x03F5;<italic>j</italic> represents the articles in a particular journal, <italic>&#x03B8;</italic><sub><italic>mk</italic></sub>  is the proportion of the <italic>k</italic>th topic on each item, and <italic>n</italic><sup><italic>j</italic></sup> is the total number of articles published in the journal <italic>j</italic>.</p><p>Topic distribution across countries was defined as the ratio of the <italic>k</italic>th topic in the country <italic>c</italic>, as in the following equation:</p><disp-formula id="E4"><label>(4)</label><mml:math id="eqn4"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msubsup><mml:mi>&#x03B8;</mml:mi><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:munder><mml:mo>&#x2211;</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>&#x2208;</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:munder><mml:msub><mml:mi>&#x03B8;</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msup><mml:mi>n</mml:mi><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo></mml:mstyle></mml:mstyle></mml:mrow></mml:mstyle></mml:math></disp-formula><p>where <italic>m</italic>&#x03F5;<italic>c</italic> represents the articles in a particular country, <italic>&#x03B8;</italic><sub><italic>mk</italic></sub> is the proportion of the <italic>k</italic>th topic on each item, and <italic>n</italic><sup><italic>c</italic></sup> is the total number of articles published in the country <italic>c</italic>.</p></sec><sec id="s2-6"><title>Statistics</title><p>With the purpose of facilitating the characterization of the topics in terms of their tendency, topic datasets were also submitted to simple regression slopes where the year, country, and journal were the dependent variables, while the proportion of the topics in the corresponding year, country, and journal was the response variable [<xref ref-type="bibr" rid="ref34">34</xref>]. From the regression slopes, we determined the directionality of these trends and set a significance threshold of <italic>P</italic>&#x003C;.01 (<xref ref-type="disp-formula" rid="E2">Eq2</xref>). Topics that showed statistically significant positive slopes were identified as having upward trends, while those with statistically significant negative slopes were in decline. Tendencies were finally visualized using the <italic>ggcorrplot</italic> library of R to represent correlation strengths as a heatmap matrix. The color-mapped matrix was subjected to advanced hierarchical clustering analysis in order to investigate and compile correlation datasets, given its visual form like a tree-shaped dendrogram. The <italic>Agnes</italic> function with <italic>Ward&#x2019;s</italic> method showed the agglomerative hierarchical clustering of variables. Each leaf of the dendrogram corresponded to one observation (variable), and the fusion height showed the dissimilarity between 2 observations on the vertical axis. A cut height for cluster identification was calculated using the Average Silhouette method [<xref ref-type="bibr" rid="ref35">35</xref>].</p></sec></sec><sec id="s3" sec-type="results"><title>Results</title><sec id="s3-1"><title>Overview of the Dataset</title><p>The consolidated dataset was obtained by combining the results and removing duplicates, totaling 39,856 articles (<xref ref-type="fig" rid="figure1">Figure 1</xref>). After the relevant Excel file was created, 4628 articles lacking titles, abstracts, or affiliations were removed. Within this extensive dataset, 35,228 documents were assembled, demonstrating an annual growth rate of 9.86%. The extensive summary of the key descriptive characteristics pertaining to RCC from 1974 to 2023 can be found in <xref ref-type="table" rid="table2">Table 2</xref>. A substantial number of information sources, 3070 in total, were revealed by the data. Given that the document&#x2019;s average age was 11.6 years (the time since the publication of the examined articles), it is likely that much of the research was carried out some time ago. On average, however, each document received 32.35 citations, demonstrating their influence and recognition in the field (<xref ref-type="table" rid="table2">Table 2</xref>).</p><fig position="float" id="figure1"><label>Figure 1.</label><caption><p>The workflow for article selection and bibliometric analysis in renal cell carcinoma using the PubMed and Scopus databases.</p></caption><graphic alt-version="no" mimetype="image" position="float" xlink:type="simple" xlink:href="cancer_v12i1e78797_fig01.png"/></fig><table-wrap id="t2" position="float"><label>Table 2.</label><caption><p>Comprehensive overview of key descriptive characteristics and publication metrics on renal cell carcinoma from 1974 to 2023. Retrieved from the PubMed and Scopus databases.</p></caption><table id="table2" frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom">Description</td><td align="left" valign="bottom">Results</td></tr></thead><tbody><tr><td align="left" valign="top" colspan="2">Main information about data</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Timespan, range</td><td align="left" valign="top">1974&#x2010;2023</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Sources (journals, books, etc), n</td><td align="left" valign="top">3070</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Total documents, n</td><td align="left" valign="top">35,228</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Annual growth rate (%), mean</td><td align="left" valign="top">9.86</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Document age (y), mean</td><td align="left" valign="top">11.6</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Citations per document, mean</td><td align="left" valign="top">32.35</td></tr><tr><td align="left" valign="top" colspan="2">Document contents, n</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Keywords plus</td><td align="left" valign="top">52,792</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Author&#x2019;s keywords</td><td align="left" valign="top">31,248</td></tr><tr><td align="left" valign="top" colspan="2">Authors, n</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Total authors</td><td align="left" valign="top">95,238</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Authors of single-authored documents</td><td align="left" valign="top">608</td></tr><tr><td align="left" valign="top" colspan="2">Author collaboration</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Single-authored docs, n</td><td align="left" valign="top">769</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Coauthors per doc, mean</td><td align="left" valign="top">7.55</td></tr><tr><td align="left" valign="top" colspan="2">Document types</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Original research</td><td align="left" valign="top">30,913</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Review</td><td align="left" valign="top">4315</td></tr></tbody></table></table-wrap><p>With respect to the yearly output of documents on RCC, <xref ref-type="fig" rid="figure2">Figure 2</xref> provides an overview of increased production from 1974 (24 articles) to 2023 (2401 articles). Throughout the 1980s and 1990s, the document production grew modestly. However, the 2000s saw a significant increase in production, reaching a peak in 2017 (1832 articles) and indicating a solid trend in recent years. <xref ref-type="table" rid="table3">Table 3</xref> lists the top 30 scientific journals, while a global map (<xref ref-type="fig" rid="figure3">Figure 3</xref>) shows the 118 countries that were involved in RCC research. With 10,308 publications, the United States clearly was the top contributor.</p><fig position="float" id="figure2"><label>Figure 2.</label><caption><p>Annual production of documents on renal cell carcinoma from 1974 to 2023.</p></caption><graphic alt-version="no" mimetype="image" position="float" xlink:type="simple" xlink:href="cancer_v12i1e78797_fig02.png"/></fig><table-wrap id="t3" position="float"><label>Table 3.</label><caption><p>Top 30 scientific journals for research on renal cell carcinoma based on articles published between 1974 and 2023.</p></caption><table id="table3" frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom">Source</td><td align="left" valign="bottom">Abbreviation</td><td align="left" valign="bottom">Articles, n</td></tr></thead><tbody><tr><td align="left" valign="top"><italic>Journal of Urology</italic></td><td align="left" valign="top"><italic>J Urol</italic></td><td align="left" valign="top">1161</td></tr><tr><td align="left" valign="top"><italic>Urology</italic></td><td align="left" valign="top"><italic>Urology</italic></td><td align="left" valign="top">839</td></tr><tr><td align="left" valign="top"><italic>Urologic Oncology: Seminars and Original Investigations</italic></td><td align="left" valign="top"><italic>Urol Oncol</italic></td><td align="left" valign="top">560</td></tr><tr><td align="left" valign="top"><italic>European Urology</italic></td><td align="left" valign="top"><italic>Eur Urol</italic></td><td align="left" valign="top">542</td></tr><tr><td align="left" valign="top"><italic>Frontiers in Oncology</italic></td><td align="left" valign="top"><italic>Front Oncol</italic></td><td align="left" valign="top">481</td></tr><tr><td align="left" valign="top"><italic>Cancer</italic></td><td align="left" valign="top"><italic>Cancer</italic></td><td align="left" valign="top">478</td></tr><tr><td align="left" valign="top"><italic>Clinical Genitourinary Cancer</italic></td><td align="left" valign="top"><italic>Clin Genitourin Cancer</italic></td><td align="left" valign="top">474</td></tr><tr><td align="left" valign="top"><italic>BJU International</italic></td><td align="left" valign="top"><italic>BJU Int</italic></td><td align="left" valign="top">451</td></tr><tr><td align="left" valign="top"><italic>International Journal of Urology</italic></td><td align="left" valign="top"><italic>Int J Urol</italic></td><td align="left" valign="top">422</td></tr><tr><td align="left" valign="top"><italic>Oncotarget</italic></td><td align="left" valign="top"><italic>Oncotarget</italic></td><td align="left" valign="top">363</td></tr><tr><td align="left" valign="top"><italic>PLOS One</italic></td><td align="left" valign="top"><italic>PLoS One</italic></td><td align="left" valign="top">362</td></tr><tr><td align="left" valign="top"><italic>Cancers</italic></td><td align="left" valign="top"><italic>Cancers</italic></td><td align="left" valign="top">350</td></tr><tr><td align="left" valign="top"><italic>Urologia Internationalis</italic></td><td align="left" valign="top"><italic>Urol Int</italic></td><td align="left" valign="top">316</td></tr><tr><td align="left" valign="top"><italic>International Journal of Cancer</italic></td><td align="left" valign="top"><italic>Int J Cancer</italic></td><td align="left" valign="top">311</td></tr><tr><td align="left" valign="top">Clinical Cancer Research</td><td align="left" valign="top"><italic>Clin Cancer Res</italic></td><td align="left" valign="top">308</td></tr><tr><td align="left" valign="top"><italic>Oncology Letters</italic></td><td align="left" valign="top"><italic>Oncol Lett</italic></td><td align="left" valign="top">307</td></tr><tr><td align="left" valign="top"><italic>World Journal of Urology</italic></td><td align="left" valign="top"><italic>World J Urol</italic></td><td align="left" valign="top">297</td></tr><tr><td align="left" valign="top"><italic>British Journal of Cancer</italic></td><td align="left" valign="top"><italic>Brit J Cancer</italic></td><td align="left" valign="top">291</td></tr><tr><td align="left" valign="top"><italic>BMC Cancer</italic></td><td align="left" valign="top"><italic>BMC Cancer</italic></td><td align="left" valign="top">273</td></tr><tr><td align="left" valign="top"><italic>Scientific Reports</italic></td><td align="left" valign="top"><italic>Sci Rep</italic></td><td align="left" valign="top">248</td></tr><tr><td align="left" valign="top"><italic>American Journal of Surgical Pathology</italic></td><td align="left" valign="top"><italic>Am J Surg Pathol</italic></td><td align="left" valign="top">236</td></tr><tr><td align="left" valign="top"><italic>American Journal of Roentgenology</italic></td><td align="left" valign="top"><italic>Am J Roentgenol</italic></td><td align="left" valign="top">210</td></tr><tr><td align="left" valign="top"><italic>Journal of Clinical Oncology</italic></td><td align="left" valign="top"><italic>J Clin Oncol</italic></td><td align="left" valign="top">206</td></tr><tr><td align="left" valign="top"><italic>Cancer Research</italic></td><td align="left" valign="top"><italic>Cancer Res</italic></td><td align="left" valign="top">200</td></tr><tr><td align="left" valign="top"><italic>Human Pathology</italic></td><td align="left" valign="top"><italic>Hum Pathol</italic></td><td align="left" valign="top">196</td></tr><tr><td align="left" valign="top"><italic>Oncology Reports</italic></td><td align="left" valign="top"><italic>Oncol Rep</italic></td><td align="left" valign="top">189</td></tr><tr><td align="left" valign="top"><italic>International Urology and Nephrology</italic></td><td align="left" valign="top"><italic>Int Urol Nephrol</italic></td><td align="left" valign="top">188</td></tr><tr><td align="left" valign="top"><italic>International Journal of Molecular Sciences</italic></td><td align="left" valign="top"><italic>Int J Mol Sci</italic></td><td align="left" valign="top">186</td></tr><tr><td align="left" valign="top"><italic>Medicine (United States)</italic></td><td align="left" valign="top"><italic>Med (United States)</italic></td><td align="left" valign="top">172</td></tr><tr><td align="left" valign="top"><italic>Journal of Endourology</italic></td><td align="left" valign="top"><italic>J Endourol</italic></td><td align="left" valign="top">165</td></tr></tbody></table></table-wrap><fig position="float" id="figure3"><label>Figure 3.</label><caption><p>Distribution of geographical origins in the analysis of 35,228 published articles on renal cell carcinoma from 1974 to 2023. The table displays the top 30 countries with the highest research production.</p></caption><graphic alt-version="no" mimetype="image" position="float" xlink:type="simple" xlink:href="cancer_v12i1e78797_fig03.png"/></fig></sec><sec id="s3-2"><title>Latent Dirichlet Allocation</title><p>The methodological rigor, reproducibility, and accuracy of LDA were ensured using advanced bibliometric tools such as Bibliometrix and Textminer. There were 30 topics with the best coherence score in the LDA model (<xref ref-type="fig" rid="figure4">Figure 4</xref>). The terms with the highest probabilities and semantically relevant labels for each latent topic are shown in <xref ref-type="table" rid="table4">Table 4</xref>.</p><table-wrap id="t4" position="float"><label>Table 4.</label><caption><p>Topics discovered from 35,228 articles on renal cell carcinoma published between 1974 and 2023.</p></caption><table id="table4" frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom">Terms</td><td align="left" valign="bottom">Article numbers, n</td><td align="left" valign="bottom">Top terms</td><td align="left" valign="bottom">Label</td><td align="left" valign="bottom">Themes</td><td align="left" valign="bottom">Prevalence (%)</td></tr></thead><tbody><tr><td align="left" valign="top">t_1</td><td align="left" valign="top">1411</td><td align="left" valign="top">inhibitor, sunitinib, treatment, target, drug, kinas, vegf, growth, factor, tki, sorafenib, resist, agent, tyrosin, growth_factor</td><td align="left" valign="top">Inhibitors in treatment</td><td align="left" valign="top">Treatment and therapies</td><td align="left" valign="top">3.455</td></tr><tr><td align="left" valign="top">t_2</td><td align="left" valign="top">563</td><td align="left" valign="top">rcc, level, patient, serum, control, rcc_patient, increas, group, concentr, elev, blood, distribut, plasma, healthi, compar</td><td align="left" valign="top">Serum levels and patient control</td><td align="left" valign="top">Diagnosis and evaluation</td><td align="left" valign="top">2.414</td></tr><tr><td align="left" valign="top">t_3</td><td align="left" valign="top">1240</td><td align="left" valign="top">express, tissu, normal, protein, tumor, level, correl, mrna, sampl, kidnei, posit, compar, marker, normal_tissu, express_level</td><td align="left" valign="top">Protein expression in tissues and tumors</td><td align="left" valign="top">Biomolecular and genetic characteristics</td><td align="left" valign="top">3.866</td></tr><tr><td align="left" valign="top">t_4</td><td align="left" valign="top">1370</td><td align="left" valign="top">gene, mutat, tumor, chromosom, genet, dna, loss, alter, famili, sequenc, region, identifi, methyl, variant, r</td><td align="left" valign="top">Genetic mutations and chromosomal alterations</td><td align="left" valign="top">Biomolecular and genetic characteristics</td><td align="left" valign="top">3.067</td></tr><tr><td align="left" valign="top">t_5</td><td align="left" valign="top">2113</td><td align="left" valign="top">rcc, clear, tumor, papillari, type, case, subtyp, carcinoma, featur, clear_rcc, prcc, posit, chromophob, histolog, pattern</td><td align="left" valign="top">Histological features and subtypes</td><td align="left" valign="top">Disease characteristics and progression</td><td align="left" valign="top">4.537</td></tr><tr><td align="left" valign="top">t_6</td><td align="left" valign="top">1293</td><td align="left" valign="top">tumor, surgic, thrombu, complic, oper, nephrectomi, surgeri, resect, laparoscop, blood, vena, ivc, postop, perform, approach</td><td align="left" valign="top">Surgical approaches and complications</td><td align="left" valign="top">Pathological features</td><td align="left" valign="top">3.053</td></tr><tr><td align="left" valign="top">t_7</td><td align="left" valign="top">939</td><td align="left" valign="top">vhl, &#x00CE;&#x00B1;, hif, factor, &#x00CE;&#x00B2;, hif_&#x00CE;&#x00B1;, protein, hypoxia, activ, induc, von, lindau, hippel, hippel_lindau, von_hippel</td><td align="left" valign="top">Hypoxia factors and related proteins</td><td align="left" valign="top">Pathological features</td><td align="left" valign="top">2.654</td></tr><tr><td align="left" valign="top">t_8</td><td align="left" valign="top">575</td><td align="left" valign="top">effect, treatment, ablat, control, local, search, evid, review, includ, meta, radiat, perform, systemat, outcom, percutan</td><td align="left" valign="top">Treatment effects and local ablation</td><td align="left" valign="top">Treatment and therapies</td><td align="left" valign="top">2.281</td></tr><tr><td align="left" valign="top">t_9</td><td align="left" valign="top">770</td><td align="left" valign="top">immun, pd, respons, immunotherapi, combin, nivolumab, checkpoint, ici, inhibitor, immun_checkpoint, therapi, checkpoint_inhibitor, treatment, death, anti</td><td align="left" valign="top">Immunotherapy and immune responses</td><td align="left" valign="top">Treatment and therapies</td><td align="left" valign="top">2.416</td></tr><tr><td align="left" valign="top">t_10</td><td align="left" valign="top">544</td><td align="left" valign="top">model, predict, score, risk, base, valid, group, curv, clinic, perform, cohort, featur, characterist, set, auc</td><td align="left" valign="top">Risk prediction models and clinical assessment</td><td align="left" valign="top">Epidemiology and risk factors</td><td align="left" valign="top">2.782</td></tr><tr><td align="left" valign="top">t_11</td><td align="left" valign="top">1593</td><td align="left" valign="top">imag, ct, enhanc, lesion, mass, contrast, evalu, tomographi, mri, comput, detect, phase, comput_tomographi, scan, find</td><td align="left" valign="top">Diagnostic imaging and radiological evaluation</td><td align="left" valign="top">Diagnosis and evaluation</td><td align="left" valign="top">3.633</td></tr><tr><td align="left" valign="top">t_12</td><td align="left" valign="top">1794</td><td align="left" valign="top">patient, month, surviv, median, mrcc, progress, o, group, pf, treat, metastat, free, line, progress_free, receiv</td><td align="left" valign="top">Survival and disease progression</td><td align="left" valign="top">Disease characteristics and progression</td><td align="left" valign="top">4.504</td></tr><tr><td align="left" valign="top">t_13</td><td align="left" valign="top">125</td><td align="left" valign="top">tumor, node, lymph, lymph_node, invas, metastasi, distant, involv, stage, crcc, posit, distant_metastasi, presenc, patient, node_metastasi</td><td align="left" valign="top">Metastasis and lymph node involvement</td><td align="left" valign="top">Metastasis and dissemination</td><td align="left" valign="top">1.776</td></tr><tr><td align="left" valign="top">t_14</td><td align="left" valign="top">724</td><td align="left" valign="top">metastat, metastas, metastasi, primari, patient, bone, site, rcc, lung, lesion, brain, primari_tumor, resect, pet, diseas</td><td align="left" valign="top">Metastasis and lesions in other organs</td><td align="left" valign="top">Metastasis and dissemination</td><td align="left" valign="top">2.724</td></tr><tr><td align="left" valign="top">t_15</td><td align="left" valign="top">324</td><td align="left" valign="top">patient, syndrom, develop, symptom, diseas, clinic, common, earli, relat, occur, sever, adult, hypertens, infect, manifest</td><td align="left" valign="top">Syndromes and clinical manifestations</td><td align="left" valign="top">Pathological features</td><td align="left" valign="top">2.108</td></tr><tr><td align="left" valign="top">t_16</td><td align="left" valign="top">1969</td><td align="left" valign="top">tumor, activ, human, effect, induc, increas, mice, antibodi, antigen, anti, deriv, specif, growth, line, cytotox</td><td align="left" valign="top">Tumor activity and immune responses</td><td align="left" valign="top">Disease characteristics and progression</td><td align="left" valign="top">4.218</td></tr><tr><td align="left" valign="top">t_17</td><td align="left" valign="top">2190</td><td align="left" valign="top">patient, nephrectomi, year, recurr, group, surgeri, follow, rate, rang, underw, local, radic, month, partial, diseas</td><td align="left" valign="top">Nephrectomy and recurrence</td><td align="left" valign="top">Metastasis and dissemination</td><td align="left" valign="top">5.242</td></tr><tr><td align="left" valign="top">t_18</td><td align="left" valign="top">1147</td><td align="left" valign="top">rcc, risk, ci, increas, associ, ag, patient, incid, compar, ratio, popul, year, mortal, interv, data</td><td align="left" valign="top">Risk factors and epidemiology</td><td align="left" valign="top">Epidemiology and risk factors</td><td align="left" valign="top">3.858</td></tr><tr><td align="left" valign="top">t_19</td><td align="left" valign="top">2049</td><td align="left" valign="top">patient, respons, treatment, dose, toxic, dai, week, event, advers, receiv, diseas, progress, evalu, phase, efficaci</td><td align="left" valign="top">Toxicity and adverse events in treatments</td><td align="left" valign="top">Pathological features</td><td align="left" valign="top">4.779</td></tr><tr><td align="left" valign="top">t_20</td><td align="left" valign="top">102</td><td align="left" valign="top">bladder, prostat, urolog, urinari, health, urotheli, tsc, prostat_cancer, malign, kluwer, lippincott, wolter, wolter_kluwer, william, wilkin</td><td align="left" valign="top">Urological cancers and related conditions</td><td align="left" valign="top">Related conditions</td><td align="left" valign="top">1.628</td></tr><tr><td align="left" valign="top">t_21</td><td align="left" valign="top">351</td><td align="left" valign="top">kidnei, diseas, long, term, transplant, function, long_term, develop, chronic, kidnei_diseas, egfr, diabet, dialysi, donor, recipi</td><td align="left" valign="top">Chronic kidney disease and transplant</td><td align="left" valign="top">Related conditions</td><td align="left" valign="top">1.967</td></tr><tr><td align="left" valign="top">t_22</td><td align="left" valign="top">1917</td><td align="left" valign="top">ccrcc, gene, clear, identifi, express, relat, prognosi, clear_ccrcc, ccrcc_patient, cancer, pathwai, biomark, potenti, data, genom</td><td align="left" valign="top">Gene expression and prognosis</td><td align="left" valign="top">Biomolecular and genetic characteristics</td><td align="left" valign="top">4.362</td></tr><tr><td align="left" valign="top">t_23</td><td align="left" valign="top">487</td><td align="left" valign="top">develop, molecular, potenti, recent, therapeut, provid, approach, clinic, understand, import, review, research, base, applic, strategi</td><td align="left" valign="top">Molecular advances and therapeutics</td><td align="left" valign="top">Pathological features</td><td align="left" valign="top">3.026</td></tr><tr><td align="left" valign="top">t_24</td><td align="left" valign="top">1388</td><td align="left" valign="top">surviv, patient, prognost, factor, independ, multivari, specif, cox, o, prognosi, free, prognost_factor, outcom, predictor, specif_surviv</td><td align="left" valign="top">Prognostic factors and survival</td><td align="left" valign="top">Disease characteristics and progression</td><td align="left" valign="top">4.137</td></tr><tr><td align="left" valign="top">t_25</td><td align="left" valign="top">202</td><td align="left" valign="top">cancer, type, lung, breast, kidnei_cancer, melanoma, cancer_patient, includ, lung_cancer, small, breast_cancer, research, acid, metabol, colorect</td><td align="left" valign="top">Nonrenal cancers and comparative analysis</td><td align="left" valign="top">Pathological features</td><td align="left" valign="top">2.354</td></tr><tr><td align="left" valign="top">t_26</td><td align="left" valign="top">555</td><td align="left" valign="top">malign, tumor, diagnosi, biopsi, benign, pancreat, neoplasm, thyroid, mass, case, diagnost, lesion, diagnos, carcinoma, small</td><td align="left" valign="top">Diagnosis and characterization of tumors</td><td align="left" valign="top">Diagnosis and evaluation</td><td align="left" valign="top">2.559</td></tr><tr><td align="left" valign="top">t_27</td><td align="left" valign="top">3022</td><td align="left" valign="top">rcc, mir, prolifer, inhibit, express, role, regul, assai, line, invas, effect, target, apoptosi, promot, migrat</td><td align="left" valign="top">Gene regulation and microRNA expression</td><td align="left" valign="top">Biomolecular and genetic characteristics</td><td align="left" valign="top">5.728</td></tr><tr><td align="left" valign="top">t_28</td><td align="left" valign="top">604</td><td align="left" valign="top">tumor, stage, grade, size, patholog, pt, tumor_size, low, nuclear, clinic, fuhrman, correl, necrosi, fuhrman_grade, tnm</td><td align="left" valign="top">Staging and pathological features</td><td align="left" valign="top">Pathological features</td><td align="left" valign="top">2.986</td></tr><tr><td align="left" valign="top">t_29</td><td align="left" valign="top">1168</td><td align="left" valign="top">therapi, treatment, clinic, target, improv, trial, advanc, system, review, manag, metastat, rcc, target_therapi, benefit, diseas</td><td align="left" valign="top">Advanced therapies and management of metastatic disease</td><td align="left" valign="top">Treatment and therapies</td><td align="left" valign="top">3.795</td></tr><tr><td align="left" valign="top">t_30</td><td align="left" valign="top">2699</td><td align="left" valign="top">case, report, year, present, rare, reveal, kidnei, left, mass, diagnosi, adren, report_case, examin, diagnos, literatur</td><td align="left" valign="top">Clinical presentation and diagnosis of rare cases</td><td align="left" valign="top">Diagnosis and evaluation</td><td align="left" valign="top">4.089</td></tr></tbody></table></table-wrap><fig position="float" id="figure4"><label>Figure 4.</label><caption><p>Evaluation of coherence scores for topic models in oncology across different numbers of topics (<italic>k</italic>). Coherence: measures the semantic quality of topics. Higher values indicate stronger word relationships. Topic models: identify thematic patterns in texts; in oncology, they reveal key research areas; <italic>k</italic> represents the number of topics in the model. Helps determine the optimal value for thematic analysis.</p></caption><graphic alt-version="no" mimetype="image" position="float" xlink:type="simple" xlink:href="cancer_v12i1e78797_fig04.png"/></fig><p>The 30 identified topics were in 8 crucial domains of RCC research:</p><list list-type="bullet"><list-item><p>Treatment and Therapies: This category focused on different approaches to treating RCC, including targeted inhibitors (t_1), local ablation effects (t_8), immunotherapy responses (t_9), and advanced management of metastatic disease (t_29).</p></list-item><list-item><p>Biomolecular and Genetic Characteristics: Here, the emphasis was on understanding the molecular and genetic makeup of RCC, covering topics like protein expression in tissues and tumors (t_3, t_22, and t_27) and genetic mutations and chromosomal alterations (t_4).</p></list-item><list-item><p>Disease Characteristics and Progression: This category delved into the histological features and subtypes of RCC (t_5), as well as the dynamics of tumor activity and immune responses (t_16), and survival rates and disease progression (t_12 and t_24) and pathological features (t_28).</p></list-item><list-item><p>Diagnosis and Evaluation: Topics in this category included diagnostic imaging and radiological evaluation (t_2 and t_11) for RCC detection and the characterization of tumors (t_26 and t_30) for accurate diagnosis.</p></list-item><list-item><p>Metastasis and Dissemination: Here, the focus was on understanding how RCC spreads, including its involvement with lymph nodes (t_13), lesions in other organs (t_14), and the recurrence of the disease post nephrectomy (t_17).</p></list-item><list-item><p>Epidemiology and Risk Factors: This category examined the risk prediction models and clinical assessment tools (t_10) used to evaluate RCC risk, as well as the epidemiological factors associated with the disease (t_18).</p></list-item><list-item><p>Related Conditions: Topics here explored conditions related to RCC, such as urological cancers (t_20), chronic kidney disease, and transplant issues (t_21).</p></list-item><list-item><p>Pathological Features: Finally, this category encompassed various pathological features of RCC, including surgical approaches and complications (t_6), hypoxia factors and related proteins (t_7), syndromes and clinical manifestations (t_15), toxicity and adverse events in treatments (t_19), molecular advances and therapeutics (t_23), and comparisons with nonrenal cancers (t_25).</p></list-item></list></sec><sec id="s3-3"><title>Topic Trends</title><p>The topic distribution by document <inline-formula><mml:math id="ieqn2"><mml:msub><mml:mrow><mml:mi>&#x03B8;</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> was added to compute the average probability <inline-formula><mml:math id="ieqn3"><mml:msubsup><mml:mrow><mml:mi>&#x03B8;</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>y</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> of all the articles published in a particular year to identify the trends (<xref ref-type="fig" rid="figure5">Figure 5</xref>). We found that the probabilities of some topics steadily increased over time (red). Black indicates topics with no discernible trend, whereas blue denotes topics with a decreasing behavior.</p><fig position="float" id="figure5"><label>Figure 5.</label><caption><p>Trends of research topics in renal cell carcinoma between 1973 and 2023: increasing (red), decreasing (blue), and stable (black) topic dynamics over time.</p></caption><graphic alt-version="no" mimetype="image" position="float" xlink:type="simple" xlink:href="cancer_v12i1e78797_fig05.png"/></fig></sec><sec id="s3-4"><title>Heatmaps</title><p>Although the discovery of 30 unique themes with high coherence scores, a granular and nuanced analysis of the research landscape, was made possible by the LDA method, there was a need for validating the theme output by a form of visual data analytics. Heatmaps helped examine and understand how thematic patterns were related to variables like publication year, country, and journal. Red highlighting indicates the strongest associations among variables, reflecting higher correlation levels.</p><p><xref ref-type="fig" rid="figure6">Figure 6A</xref> illustrates correlations between specific topics and years. Red highlighting indicates the strongest associations among variables, reflecting higher correlation levels. For example, within Cluster 4, Topic 16 (t_16) &#x201C;Tumor Activity and Immune Responses&#x201D; is primarily associated with the years 1993, 1985, 1988, 1990, 1992, 1991, 1989, 1995, 1994, 1996, and 1999. Topic 17 (t_17) &#x201C;Nephrectomy and Recurrence&#x201D; exhibits stronger correlations with the years 1993, 1990, 1992, 1991, 1989, 1995, and 1994. In Cluster 3, Topic 22 (t_22) &#x201C;Gene Expression and Prognosis&#x201D; significantly correlates with the years 2020, 2021, 2022, and 2023, while Topic 27 (t_27), also addressing &#x201C;Gene Regulation and microRNA Expression,&#x201D; shows significant associations with the years 2017, 2018, 2019, and 2020. Finally, in group 3, Topic Thirty30 (t_30) &#x201C;Clinical Presentation and Diagnosis of Rare Cases&#x201D; is linked with the years 1982, 1983, 1981, 1978, 1977, and 1975.</p><fig position="float" id="figure6"><label>Figure 6.</label><caption><p>Heatmaps to correlate topics with year (A), country (B), and source (C).</p></caption><graphic alt-version="no" mimetype="image" position="float" xlink:type="simple" xlink:href="cancer_v12i1e78797_fig06.png"/></fig><p><xref ref-type="fig" rid="figure6">Figure 6B</xref> presents the interactions between countries and topics across different groups. In group 1, Topic 27 (t_27), &#x201C;Gene Regulation and microRNA Expression,&#x201D; is predominantly correlated with Taiwan. Group 2&#x2019;s topics, &#x201C;Tumor Activity and Immune Responses&#x201D; and &#x201C;Toxicity and Adverse Events in Treatments,&#x201D; are closely associated with the Netherlands. For group 3, &#x201C;Survival and Disease Progression&#x201D; shows significant correlations with the Czech Republic, Denmark, Belgium, France, and Italy, and &#x201C;Nephrectomy and Recurrence&#x201D; is notably linked with Israel and South Korea. Lastly, in group 4, &#x201C;Gene Expression and Prognosis&#x201D; and &#x201C;Gene Regulation and microRNA Expression&#x201D; are primarily connected with China.</p><p><xref ref-type="fig" rid="figure6">Figure 6C</xref> outlines the dominant publication patterns for specific topics within various journals. In group 1, &#x201C;Tumor Activity and Immune Responses&#x201D; is predominantly linked with the <italic>International Journal of Cancer</italic> and <italic>Cancer Research</italic>. Group 2&#x2019;s topic, &#x201C;Gene Expression and Prognosis,&#x201D; has a significant association with <italic>Frontiers in Oncology</italic>. In group 3, &#x201C;Survival and Disease Progression&#x201D; relates to <italic>Clinical Genitourinary Cancer</italic>, and &#x201C;Nephrectomy and Recurrence&#x201D; is associated with <italic>BJU International</italic>, <italic>Journal of Endourology</italic>, and <italic>Urology</italic>. Lastly, in group 4, &#x201C;Diagnostic Imaging and Radiological Evaluation&#x201D; is prominently linked to the <italic>American Journal of Roentgenology</italic>. LDA algorithm&#x2019;s identification of the key RCC research themes was mirrored in the relevant clustergrams that emerged from the hierarchical cluster analysis of the heatmaps.</p></sec></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><sec id="s4-1"><title>Principal Findings</title><p>By displaying each topic as a group of related words, LDA was able to identify latent (hidden) topics within a corpus of documents and demonstrate how each document may be represented as a combination of these topics. According to this method, RCC research has evolved over the past 50 years from concentrating on surgery to comprehending its genetic underpinnings and the impact of new treatments like immune checkpoint inhibitors and targeted therapies, which have improved the prognosis of metastatic RCC.</p><p>The disease characterization, progression, and pathological features have dominated the RCC research landscape for the past 50 years (t_16 and t_19) [<xref ref-type="bibr" rid="ref10">10</xref>]. Kidney cancer was regarded as a single disease until the <italic>VHL</italic> gene was discovered [<xref ref-type="bibr" rid="ref9">9</xref>]. Since then, scientists have realized that kidney cancer is a multitude of diverse diseases, each with its own genetic makeup. Although the characterization of genetic mutations and chromosomal alterations linked to the growth of RCC [<xref ref-type="bibr" rid="ref36">36</xref>,<xref ref-type="bibr" rid="ref37">37</xref>] has recently improved our knowledge of this kidney cancer (t_22), RCC research does emphasize the necessity of assessment of treatment effects&#x2019; safety and efficacy, as well as surveillance of RCC recurrence following nephrectomy. Therefore, a better understanding of resistance mechanisms, molecular prognosis (t_22), and immunological responses (t_16) is essential.</p><p>The advances in omics technologies over the last 10 years constitute a promising area of personalized RCC cure [<xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref38">38</xref>,<xref ref-type="bibr" rid="ref39">39</xref>]. In addition, the microRNA signature in RCC and its function in progression, diagnosis, therapy targeting, and prognosis of RCC (t_27) have also received particular attention [<xref ref-type="bibr" rid="ref40">40</xref>,<xref ref-type="bibr" rid="ref41">41</xref>]. Recent RCC research also moves toward earlier cancer detection through broad imaging and radiological evolution (t-11). RCC has a difficult pathological classification, since the histological analysis reveals three most recurrent sporadic types: clear-cell RCC (70%&#x2010;75%), papillary RCC (10%&#x2010;15%), and chromophobe RCC (5%) [<xref ref-type="bibr" rid="ref42">42</xref>]. It is predicated on morphologies, architecture, underlying genetic abnormalities, and tumoral protein expression [<xref ref-type="bibr" rid="ref43">43</xref>,<xref ref-type="bibr" rid="ref44">44</xref>]. Pathologists can detect these malignancies more accurately and provide better treatment plans and patient outcomes if they are aware of the significance of these markers (t_12 and t_19).</p><p>A major cause for worry is the postoperative surveillance of RCC recurrence following nephrectomy (t_17) [<xref ref-type="bibr" rid="ref45">45</xref>]. Research on local RCC ablation and assessment of treatment effects on safety and efficacy is still ongoing (t_12, t_16, and t_19). The discovery of tailored medication like tyrosine kinase inhibitors (also called TKIs), such as Sunitinib and Sorafenib, has been beneficial in treating metastatic RCC [<xref ref-type="bibr" rid="ref46">46</xref>,<xref ref-type="bibr" rid="ref47">47</xref>]. Another well-established component of RCC treatment is checkpoint inhibitor immunotherapy [<xref ref-type="bibr" rid="ref48">48</xref>], which shows its superior therapeutic efficacy when combined with TKIs [<xref ref-type="bibr" rid="ref49">49</xref>]. The next generation of TKIs and immunotherapy (t_16) [<xref ref-type="bibr" rid="ref50">50</xref>] is being developed to overcome some unfavorable outcomes with kinase inhibitors [<xref ref-type="bibr" rid="ref51">51</xref>,<xref ref-type="bibr" rid="ref52">52</xref>] and immunotherapy (t_19) [<xref ref-type="bibr" rid="ref53">53</xref>], as well as the emergence of drug resistance [<xref ref-type="bibr" rid="ref54">54</xref>]. Only a small number of themes still earn little attention. The topics &#x201C;Serum Levels and Patient Control&#x201D; (t_2), &#x201C;Hypoxia Factors and Related Proteins&#x201D; (t_7), and &#x201C;Risk Prediction Models and Clinical Assessment&#x201D; (t_18) are overlooked and should require additional attention.</p><p>In line with the LDA analysis and our own scientific expectations and goals, it was also feasible to identify untapped topics that have not yet been covered by scholarly literature. Intriguing lines of inquiry are the prognostic value of vascular endothelial growth factor [<xref ref-type="bibr" rid="ref55">55</xref>], endostatin [<xref ref-type="bibr" rid="ref56">56</xref>], C-reactive protein [<xref ref-type="bibr" rid="ref57">57</xref>], the hypoxia-induced pathway [<xref ref-type="bibr" rid="ref58">58</xref>], and ferroptosis [<xref ref-type="bibr" rid="ref59">59</xref>]. The involvement of chronic inflammation [<xref ref-type="bibr" rid="ref60">60</xref>] and gut and urinary microbiota in immune modulation of metastatic RCC [<xref ref-type="bibr" rid="ref61">61</xref>] remains poorly investigated. Clinical judgments and patient stratification in RCC may be enhanced by the creation of new predictive models [<xref ref-type="bibr" rid="ref62">62</xref>] based on, for instance, genetic biomarkers [<xref ref-type="bibr" rid="ref63">63</xref>]. The application of artificial intelligence is another potential topic that could help physicians in identifying RCC subtypes by analyzing computed tomography scans, as well as in deconstructing complex epidemiological and environmental factors that influence RCC occurrence, like hypoxia [<xref ref-type="bibr" rid="ref64">64</xref>].</p><p>In contrast to traditional bibliometric analysis, the LDA approach effectively extracted potential themes and inferred implicit information from a large collection of documents. The LDA approach and other topic modeling methods like co-citation and keyword co-occurrence cannot be compared with the same conceptual granularity or depth. LDA goes beyond who cites whom (ie, intellectual connection and research lineage) and uncovers the underlying conceptual themes that bind the literature, which may not be immediately apparent from citation patterns alone. Unlike a list of keywords, which reveals basic relationships, LDA organizes these co-occurring words into meaningful higher-order themes, offering a more detailed knowledge of topic relationships and structure. For this reason, the LDA analysis was not affected by the potential simplicity of the keywords chosen in the study.</p><p>The subjectivity involved in manually labeling LDA topics, the possibility of missing publications by using only 2 databases, the linguistic bias introduced by excluding articles written in languages other than English, the constraints of the &#x201C;bag-of-words&#x201D; model which disregards grammar and context, and the effects of excluding literature like book chapters are some limitations of the study. Despite the constraints, LDA can disclose &#x201C;unknown unknowns&#x201D; by revealing unarticulated or unacknowledged themes. It can also give an overview of the research landscape to identify new topics and interdisciplinary connections, as well as demonstrate how old themes are resurfacing in new ones. As a result, LDA remains the most often used natural language model [<xref ref-type="bibr" rid="ref13">13</xref>,<xref ref-type="bibr" rid="ref14">14</xref>,<xref ref-type="bibr" rid="ref65">65</xref>].</p></sec><sec id="s4-2"><title>Conclusions</title><p>This review offered a thorough summary of how research on RCC has changed over the previous 50 years. LDA helped identify important emerging trends in treatment development to address drug resistance and undesirable side effects, surgical techniques, and immunotherapy advancements, among other topics pertinent to clinical practice and medical research. In summary, this study presents a methodological synthesis of the development of RCC research and delivers pertinent data for clinical decision-making, early identification, and the planning of new biomedical research.</p></sec></sec></body><back><notes><sec><title>Funding</title><p>No external financial support or grants were received from any public, commercial, or not-for-profit entities for the research, authorship, or publication of this article.</p></sec><sec><title>Data Availability</title><p>The datasets generated or analyzed during this study are available from the corresponding author on reasonable request.</p></sec></notes><fn-group><fn fn-type="con"><p>Conceptualization: JDLH-M, KM-E</p><p>Data curation: KM-E, JDLH-M</p><p>Formal analysis: JDLH-M, KM-E, CAS-M</p><p>Investigation: JDLH-M, KM-E, CAS-M, MF, SJB</p><p>Methodology: JDLH-M, KM-E, CAS-M</p><p>Supervision: MF, SJB</p><p>Validation: JDLH-M, KM-E, CAS-M, MF, SJB</p><p>Writing &#x2013; original draft: KM-E, SJB</p><p>Writing &#x2013; review &#x0026; editing: MF, SJB</p><p>All the authors equally contributed to the writing of the final version of the manuscript and were responsible for its content.</p></fn><fn fn-type="conflict"><p>None declared.</p></fn></fn-group><glossary><title>Abbreviations</title><def-list><def-item><term id="abb1">LDA</term><def><p>latent Dirichlet allocation</p></def></def-item><def-item><term id="abb2">MeSH</term><def><p>Medical Subject Headings</p></def></def-item><def-item><term id="abb3">RCC</term><def><p>renal cell carcinoma</p></def></def-item><def-item><term id="abb4">TKI</term><def><p>tyrosine kinase inhibitor</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="ref1"><label>1</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsieh</surname><given-names>JJ</given-names> </name><name name-style="western"><surname>Purdue</surname><given-names>MP</given-names> </name><name name-style="western"><surname>Signoretti</surname><given-names>S</given-names> </name><etal/></person-group><article-title>Renal cell carcinoma</article-title><source>Nat Rev Dis Primers</source><year>2017</year><month>03</month><day>9</day><volume>3</volume><fpage>17009</fpage><pub-id pub-id-type="doi">10.1038/nrdp.2017.9</pub-id><pub-id pub-id-type="medline">28276433</pub-id></nlm-citation></ref><ref id="ref2"><label>2</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ljungberg</surname><given-names>B</given-names> </name><name name-style="western"><surname>Campbell</surname><given-names>SC</given-names> </name><name name-style="western"><surname>Choi</surname><given-names>HY</given-names> </name><etal/></person-group><article-title>The epidemiology of renal cell carcinoma</article-title><source>Eur Urol</source><year>2011</year><month>10</month><volume>60</volume><issue>4</issue><fpage>615</fpage><lpage>621</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2011.06.049</pub-id><pub-id pub-id-type="medline">21741761</pub-id></nlm-citation></ref><ref id="ref3"><label>3</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lipworth</surname><given-names>L</given-names> </name><name name-style="western"><surname>Tarone</surname><given-names>RE</given-names> </name><name name-style="western"><surname>Lund</surname><given-names>L</given-names> </name><name name-style="western"><surname>McLaughlin</surname><given-names>JK</given-names> </name></person-group><article-title>Epidemiologic characteristics and risk factors for renal cell cancer</article-title><source>Clin Epidemiol</source><year>2009</year><month>08</month><day>9</day><volume>1</volume><fpage>33</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.2147/clep.s4759</pub-id><pub-id pub-id-type="medline">20865085</pub-id></nlm-citation></ref><ref id="ref4"><label>4</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chow</surname><given-names>WH</given-names> </name><name name-style="western"><surname>Dong</surname><given-names>LM</given-names> </name><name name-style="western"><surname>Devesa</surname><given-names>SS</given-names> </name></person-group><article-title>Epidemiology and risk factors for kidney cancer</article-title><source>Nat Rev Urol</source><year>2010</year><month>05</month><volume>7</volume><issue>5</issue><fpage>245</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1038/nrurol.2010.46</pub-id><pub-id pub-id-type="medline">20448658</pub-id></nlm-citation></ref><ref id="ref5"><label>5</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haas</surname><given-names>NB</given-names> </name><name name-style="western"><surname>Nathanson</surname><given-names>KL</given-names> </name></person-group><article-title>Hereditary kidney cancer syndromes</article-title><source>Adv Chronic Kidney Dis</source><year>2014</year><month>01</month><volume>21</volume><issue>1</issue><fpage>81</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1053/j.ackd.2013.10.001</pub-id><pub-id pub-id-type="medline">24359990</pub-id></nlm-citation></ref><ref id="ref6"><label>6</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hemminki</surname><given-names>K</given-names> </name><name name-style="western"><surname>F&#x00F6;rsti</surname><given-names>A</given-names> </name><name name-style="western"><surname>Hemminki</surname><given-names>A</given-names> </name><name name-style="western"><surname>Ljungberg</surname><given-names>B</given-names> </name><name name-style="western"><surname>Hemminki</surname><given-names>O</given-names> </name></person-group><article-title>Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden</article-title><source>PLoS One</source><year>2021</year><volume>16</volume><issue>6</issue><fpage>e0253236</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0253236</pub-id><pub-id pub-id-type="medline">34157049</pub-id></nlm-citation></ref><ref id="ref7"><label>7</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bukavina</surname><given-names>L</given-names> </name><name name-style="western"><surname>Bensalah</surname><given-names>K</given-names> </name><name name-style="western"><surname>Bray</surname><given-names>F</given-names> </name><etal/></person-group><article-title>Epidemiology of renal cell carcinoma: 2022 update</article-title><source>Eur Urol</source><year>2022</year><month>11</month><volume>82</volume><issue>5</issue><fpage>529</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2022.08.019</pub-id><pub-id pub-id-type="medline">36100483</pub-id></nlm-citation></ref><ref id="ref8"><label>8</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aweys</surname><given-names>H</given-names> </name><name name-style="western"><surname>Lewis</surname><given-names>D</given-names> </name><name name-style="western"><surname>Sheriff</surname><given-names>M</given-names> </name><etal/></person-group><article-title>Renal cell cancer - insights in drug resistance mechanisms</article-title><source>Anticancer Res</source><year>2023</year><month>11</month><volume>43</volume><issue>11</issue><fpage>4781</fpage><lpage>4792</lpage><pub-id pub-id-type="doi">10.21873/anticanres.16675</pub-id><pub-id pub-id-type="medline">37909991</pub-id></nlm-citation></ref><ref id="ref9"><label>9</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cowey</surname><given-names>CL</given-names> </name><name name-style="western"><surname>Rathmell</surname><given-names>WK</given-names> </name></person-group><article-title>VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy</article-title><source>Curr Oncol Rep</source><year>2009</year><month>03</month><volume>11</volume><issue>2</issue><fpage>94</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1007/s11912-009-0015-5</pub-id><pub-id pub-id-type="medline">19216840</pub-id></nlm-citation></ref><ref id="ref10"><label>10</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cairns</surname><given-names>P</given-names> </name></person-group><article-title>Renal cell carcinoma</article-title><source>Cancer Biomark</source><year>2011</year><volume>9</volume><issue>1-6</issue><fpage>461</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.3233/CBM-2011-0176</pub-id></nlm-citation></ref><ref id="ref11"><label>11</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choueiri</surname><given-names>TK</given-names> </name><name name-style="western"><surname>Pal</surname><given-names>SK</given-names> </name><name name-style="western"><surname>Lewis</surname><given-names>B</given-names> </name><name name-style="western"><surname>Poteat</surname><given-names>S</given-names> </name><name name-style="western"><surname>Pels</surname><given-names>K</given-names> </name><name name-style="western"><surname>Hammers</surname><given-names>H</given-names> </name></person-group><article-title>The 5th Kidney Cancer Research Summit: research accelerating cures for renal cell carcinoma in 2023</article-title><source>Oncologist</source><year>2024</year><month>02</month><day>2</day><volume>29</volume><issue>2</issue><fpage>91</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1093/oncolo/oyad322</pub-id><pub-id pub-id-type="medline">38048064</pub-id></nlm-citation></ref><ref id="ref12"><label>12</label><nlm-citation citation-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Matorevhu</surname><given-names>A</given-names> </name></person-group><article-title>Bibliometrics: application opportunities and limitations</article-title><source>Bibliometrics - An Essential Methodological Tool for Research Projects</source><year>2024</year><publisher-name>IntechOpen</publisher-name><pub-id pub-id-type="doi">10.5772/intechopen.1005292</pub-id></nlm-citation></ref><ref id="ref13"><label>13</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Escobar</surname><given-names>KM</given-names> </name><name name-style="western"><surname>Vicente-Villardon</surname><given-names>JL</given-names> </name><name name-style="western"><surname>de la Hoz-M</surname><given-names>J</given-names> </name><name name-style="western"><surname>Useche-Castro</surname><given-names>LM</given-names> </name><name name-style="western"><surname>Alarc&#x00F3;n Cano</surname><given-names>DF</given-names> </name><name name-style="western"><surname>Siteneski</surname><given-names>A</given-names> </name></person-group><article-title>Frequency of neuroendocrine tumor studies: using latent Dirichlet allocation and HJ-biplot statistical methods</article-title><source>Mathematics</source><year>2021</year><volume>9</volume><issue>18</issue><fpage>2281</fpage><pub-id pub-id-type="doi">10.3390/math9182281</pub-id></nlm-citation></ref><ref id="ref14"><label>14</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De La Hoz-M</surname><given-names>J</given-names> </name><name name-style="western"><surname>Mendes</surname><given-names>S</given-names> </name><name name-style="western"><surname>Fern&#x00E1;ndez-G&#x00F3;mez</surname><given-names>MJ</given-names> </name><name name-style="western"><surname>Gonz&#x00E1;lez Silva</surname><given-names>Y</given-names> </name></person-group><article-title>Capturing the complexity of COVID-19 research: trend analysis in the first two years of the pandemic using a Bayesian probabilistic model and machine learning tools</article-title><source>Computation</source><year>2022</year><volume>10</volume><issue>9</issue><fpage>156</fpage><pub-id pub-id-type="doi">10.3390/computation10090156</pub-id></nlm-citation></ref><ref id="ref15"><label>15</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pilacuan-Bonete</surname><given-names>L</given-names> </name><name name-style="western"><surname>Galindo-Villard&#x00F3;n</surname><given-names>P</given-names> </name><name name-style="western"><surname>Delgado-&#x00C1;lvarez</surname><given-names>F</given-names> </name></person-group><article-title>HJ-Biplot as a tool to give an extra analytical boost for the latent Dirichlet assignment (LDA) model: with an application to digital news analysis about COVID-19</article-title><source>Mathematics</source><year>2022</year><volume>10</volume><issue>14</issue><fpage>2529</fpage><pub-id pub-id-type="doi">10.3390/math10142529</pub-id></nlm-citation></ref><ref id="ref16"><label>16</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>D</given-names> </name><name name-style="western"><surname>Fang</surname><given-names>A</given-names> </name><name name-style="western"><surname>Xu</surname><given-names>Z</given-names> </name></person-group><article-title>Topic research in fuzzy domain: Based on LDA topic modelling</article-title><source>Inf Sci</source><year>2023</year><month>11</month><volume>648</volume><fpage>119600</fpage><pub-id pub-id-type="doi">10.1016/j.ins.2023.119600</pub-id></nlm-citation></ref><ref id="ref17"><label>17</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blei</surname><given-names>DM</given-names> </name><name name-style="western"><surname>Ng</surname><given-names>AY</given-names> </name><name name-style="western"><surname>Jordan</surname><given-names>MI</given-names> </name></person-group><article-title>Latent Dirichlet allocation</article-title><source>J Mach Learn Res</source><year>2003</year><access-date>2025-12-24</access-date><volume>3</volume><fpage>993</fpage><lpage>1022</lpage><comment><ext-link ext-link-type="uri" xlink:href="https://www.jmlr.org/papers/volume3/blei03a/blei03a.pdf">https://www.jmlr.org/papers/volume3/blei03a/blei03a.pdf</ext-link></comment></nlm-citation></ref><ref id="ref18"><label>18</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sood</surname><given-names>A</given-names> </name><name name-style="western"><surname>Ghosh</surname><given-names>AK</given-names> </name></person-group><article-title>Literature search using PubMed: an essential tool for practicing evidence- based medicine</article-title><source>J Assoc Physicians India</source><year>2006</year><month>04</month><volume>54</volume><fpage>303</fpage><lpage>308</lpage><pub-id pub-id-type="medline">16944614</pub-id></nlm-citation></ref><ref id="ref19"><label>19</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burnham</surname><given-names>JF</given-names> </name></person-group><article-title>Scopus database: a review</article-title><source>Biomed Digit Libr</source><year>2006</year><month>03</month><day>8</day><volume>3</volume><issue>1</issue><fpage>1</fpage><pub-id pub-id-type="doi">10.1186/1742-5581-3-1</pub-id><pub-id pub-id-type="medline">16522216</pub-id></nlm-citation></ref><ref id="ref20"><label>20</label><nlm-citation citation-type="web"><source>The R Project for Statistical Computing</source><access-date>2025-12-24</access-date><comment><ext-link ext-link-type="uri" xlink:href="https://www.r-project.org/">https://www.r-project.org/</ext-link></comment></nlm-citation></ref><ref id="ref21"><label>21</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gr&#x00FC;n</surname><given-names>B</given-names> </name><name name-style="western"><surname>Hornik</surname><given-names>K</given-names> </name></person-group><article-title>Topicmodels: an R package for fitting topic models</article-title><source>J Stat Softw</source><year>2011</year><volume>40</volume><fpage>1</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.18637/jss.v040.i13</pub-id></nlm-citation></ref><ref id="ref22"><label>22</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aria</surname><given-names>M</given-names> </name><name name-style="western"><surname>Cuccurullo</surname><given-names>C</given-names> </name></person-group><article-title>bibliometrix: An R-tool for comprehensive science mapping analysis</article-title><source>J Informetr</source><year>2017</year><month>11</month><volume>11</volume><issue>4</issue><fpage>959</fpage><lpage>975</lpage><pub-id pub-id-type="doi">10.1016/j.joi.2017.08.007</pub-id></nlm-citation></ref><ref id="ref23"><label>23</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caputo</surname><given-names>A</given-names> </name><name name-style="western"><surname>Kargina</surname><given-names>M</given-names> </name></person-group><article-title>A user-friendly method to merge Scopus and Web of Science data during bibliometric analysis</article-title><source>J Market Anal</source><year>2022</year><month>03</month><volume>10</volume><issue>1</issue><fpage>82</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1057/s41270-021-00142-7</pub-id></nlm-citation></ref><ref id="ref24"><label>24</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Donthu</surname><given-names>N</given-names> </name><name name-style="western"><surname>Kumar</surname><given-names>S</given-names> </name><name name-style="western"><surname>Mukherjee</surname><given-names>D</given-names> </name><name name-style="western"><surname>Pandey</surname><given-names>N</given-names> </name><name name-style="western"><surname>Lim</surname><given-names>WM</given-names> </name></person-group><article-title>How to conduct a bibliometric analysis: an overview and guidelines</article-title><source>J Bus Res</source><year>2021</year><month>09</month><volume>133</volume><fpage>285</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1016/j.jbusres.2021.04.070</pub-id></nlm-citation></ref><ref id="ref25"><label>25</label><nlm-citation citation-type="confproc"><person-group person-group-type="author"><name name-style="western"><surname>Glendowne</surname><given-names>P</given-names> </name><name name-style="western"><surname>Glendowne</surname><given-names>D</given-names> </name></person-group><article-title>Interpretability of API call topic models: an exploratory study</article-title><conf-name>53rd Hawaii International Conference on System Sciences</conf-name><conf-date>Jan 7-10, 2020</conf-date><pub-id pub-id-type="doi">10.24251/HICSS.2020.793</pub-id></nlm-citation></ref><ref id="ref26"><label>26</label><nlm-citation citation-type="confproc"><person-group person-group-type="author"><name name-style="western"><surname>Syed</surname><given-names>S</given-names> </name><name name-style="western"><surname>Spruit</surname><given-names>M</given-names> </name></person-group><article-title>Full-text or abstract? Examining topic coherence scores using latent Dirichlet allocation</article-title><conf-name>2017 IEEE International Conference on Data Science and Advanced Analytics (DSAA)</conf-name><conf-date>Oct 19-21, 2017</conf-date><conf-loc>Tokyo, Japan</conf-loc><fpage>165</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1109/DSAA.2017.61</pub-id></nlm-citation></ref><ref id="ref27"><label>27</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>J</given-names> </name><name name-style="western"><surname>Chang</surname><given-names>Y</given-names> </name><name name-style="western"><surname>Liu</surname><given-names>H</given-names> </name></person-group><article-title>Mining social media with social theories</article-title><source>SIGKDD Explor Newsl</source><year>2014</year><month>06</month><day>16</day><volume>15</volume><issue>2</issue><fpage>20</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1145/2641190.2641195</pub-id></nlm-citation></ref><ref id="ref28"><label>28</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De la Hoz-M</surname><given-names>J</given-names> </name><name name-style="western"><surname>Fern&#x00E1;ndez-G&#x00F3;mez</surname><given-names>MJ</given-names> </name><name name-style="western"><surname>Mendes</surname><given-names>S</given-names> </name></person-group><article-title>LDAShiny: an R package for exploratory review of scientific literature based on a Bayesian probabilistic model and machine learning tools</article-title><source>Mathematics</source><year>2021</year><volume>9</volume><issue>14</issue><fpage>1671</fpage><pub-id pub-id-type="doi">10.3390/math9141671</pub-id></nlm-citation></ref><ref id="ref29"><label>29</label><nlm-citation citation-type="confproc"><person-group person-group-type="author"><name name-style="western"><surname>Blei</surname><given-names>DM</given-names> </name><name name-style="western"><surname>Lafferty</surname><given-names>JD</given-names> </name></person-group><article-title>Dynamic topic models</article-title><conf-name>ICML &#x2019;06: Proceedings of the 23rd International Conference on Machine Learning</conf-name><conf-date>Jun 25-29, 2006</conf-date><conf-loc>Pittsburgh, PA</conf-loc><fpage>113</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1145/1143844.1143859</pub-id></nlm-citation></ref><ref id="ref30"><label>30</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geman</surname><given-names>S</given-names> </name><name name-style="western"><surname>Geman</surname><given-names>D</given-names> </name></person-group><article-title>Stochastic relaxation, Gibbs distributions, and the Bayesian restoration of images</article-title><source>IEEE Trans Pattern Anal Mach Intell</source><year>1984</year><month>06</month><volume>6</volume><issue>6</issue><fpage>721</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.1109/tpami.1984.4767596</pub-id><pub-id pub-id-type="medline">22499653</pub-id></nlm-citation></ref><ref id="ref31"><label>31</label><nlm-citation citation-type="confproc"><person-group person-group-type="author"><name name-style="western"><surname>R&#x00F6;der</surname><given-names>M</given-names> </name><name name-style="western"><surname>Both</surname><given-names>A</given-names> </name><name name-style="western"><surname>Hinneburg</surname><given-names>A</given-names> </name></person-group><article-title>Exploring the space of topic coherence measures</article-title><conf-name>WSDM &#x2019;15: Proceedings of the Eighth ACM International Conference on Web Search and Data Mining</conf-name><conf-date>Feb 2-6, 2015</conf-date><conf-loc>Shanghai, China</conf-loc><fpage>399</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1145/2684822.2685324</pub-id></nlm-citation></ref><ref id="ref32"><label>32</label><nlm-citation citation-type="confproc"><person-group person-group-type="author"><name name-style="western"><surname>Lau</surname><given-names>JH</given-names> </name><name name-style="western"><surname>Grieser</surname><given-names>K</given-names> </name><name name-style="western"><surname>Newman</surname><given-names>D</given-names> </name><name name-style="western"><surname>Baldwin</surname><given-names>T</given-names> </name></person-group><article-title>Automatic labelling of topic models</article-title><access-date>2025-12-19</access-date><conf-name>Proceedings of the 49th Annual Meeting of the Association for Computational Linguistics: Human Language Technologies</conf-name><conf-date>Jun 19-24, 2011</conf-date><conf-loc>Portland, OR</conf-loc><fpage>1536</fpage><lpage>1545</lpage><comment><ext-link ext-link-type="uri" xlink:href="https://aclanthology.org/P11-1154/">https://aclanthology.org/P11-1154/</ext-link></comment></nlm-citation></ref><ref id="ref33"><label>33</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiong</surname><given-names>H</given-names> </name><name name-style="western"><surname>Cheng</surname><given-names>Y</given-names> </name><name name-style="western"><surname>Zhao</surname><given-names>W</given-names> </name><name name-style="western"><surname>Liu</surname><given-names>J</given-names> </name></person-group><article-title>Analyzing scientific research topics in manufacturing field using a topic model</article-title><source>Comput Ind Eng</source><year>2019</year><month>09</month><volume>135</volume><fpage>333</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1016/j.cie.2019.06.010</pub-id></nlm-citation></ref><ref id="ref34"><label>34</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Griffiths</surname><given-names>TL</given-names> </name><name name-style="western"><surname>Steyvers</surname><given-names>M</given-names> </name></person-group><article-title>Finding scientific topics</article-title><source>Proc Natl Acad Sci USA</source><year>2004</year><month>04</month><day>6</day><volume>101</volume><issue>Suppl 1</issue><fpage>5228</fpage><lpage>5235</lpage><pub-id pub-id-type="doi">10.1073/pnas.0307752101</pub-id><pub-id pub-id-type="medline">14872004</pub-id></nlm-citation></ref><ref id="ref35"><label>35</label><nlm-citation citation-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Kaufman</surname><given-names>L</given-names> </name><name name-style="western"><surname>Rousseeuw</surname><given-names>PJ</given-names> </name></person-group><source>Finding Groups in Data: An Introduction to Cluster Analysis</source><year>1990</year><publisher-name>John Wiley &#x0026; Sons</publisher-name><pub-id pub-id-type="doi">10.1002/9780470316801</pub-id><pub-id pub-id-type="other">9780471878766</pub-id></nlm-citation></ref><ref id="ref36"><label>36</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quddus</surname><given-names>MB</given-names> </name><name name-style="western"><surname>Pratt</surname><given-names>N</given-names> </name><name name-style="western"><surname>Nabi</surname><given-names>G</given-names> </name></person-group><article-title>Chromosomal aberrations in renal cell carcinoma: an overview with implications for clinical practice</article-title><source>Urol Ann</source><year>2019</year><volume>11</volume><issue>1</issue><fpage>6</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.4103/UA.UA_32_18</pub-id><pub-id pub-id-type="medline">30787564</pub-id></nlm-citation></ref><ref id="ref37"><label>37</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Testa</surname><given-names>U</given-names> </name><name name-style="western"><surname>Pelosi</surname><given-names>E</given-names> </name><name name-style="western"><surname>Castelli</surname><given-names>G</given-names> </name></person-group><article-title>Genetic alterations in renal cancers: identification of the mechanisms underlying cancer initiation and progression and of therapeutic targets</article-title><source>Medicines (Basel)</source><year>2020</year><month>07</month><day>29</day><volume>7</volume><issue>8</issue><fpage>44</fpage><pub-id pub-id-type="doi">10.3390/medicines7080044</pub-id><pub-id pub-id-type="medline">32751108</pub-id></nlm-citation></ref><ref id="ref38"><label>38</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>QK</given-names> </name><name name-style="western"><surname>Pavlovich</surname><given-names>CP</given-names> </name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names> </name><name name-style="western"><surname>Kinsinger</surname><given-names>CR</given-names> </name><name name-style="western"><surname>Chan</surname><given-names>DW</given-names> </name></person-group><article-title>Challenges and opportunities in the proteomic characterization of clear cell renal cell carcinoma (ccRCC): a critical step towards the personalized care of renal cancers</article-title><source>Semin Cancer Biol</source><year>2019</year><month>04</month><volume>55</volume><fpage>8</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2018.06.004</pub-id><pub-id pub-id-type="medline">30055950</pub-id></nlm-citation></ref><ref id="ref39"><label>39</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>R</given-names> </name><name name-style="western"><surname>Kannourakis</surname><given-names>G</given-names> </name><name name-style="western"><surname>Prithviraj</surname><given-names>P</given-names> </name><name name-style="western"><surname>Ahmed</surname><given-names>N</given-names> </name></person-group><article-title>Precision medicine: an optimal approach to patient care in renal cell carcinoma</article-title><source>Front Med (Lausanne)</source><year>2022</year><volume>9</volume><fpage>766869</fpage><pub-id pub-id-type="doi">10.3389/fmed.2022.766869</pub-id><pub-id pub-id-type="medline">35775004</pub-id></nlm-citation></ref><ref id="ref40"><label>40</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghafouri-Fard</surname><given-names>S</given-names> </name><name name-style="western"><surname>Shirvani-Farsani</surname><given-names>Z</given-names> </name><name name-style="western"><surname>Branicki</surname><given-names>W</given-names> </name><name name-style="western"><surname>Taheri</surname><given-names>M</given-names> </name></person-group><article-title>MicroRNA signature in renal cell carcinoma</article-title><source>Front Oncol</source><year>2020</year><volume>10</volume><fpage>596359</fpage><pub-id pub-id-type="doi">10.3389/fonc.2020.596359</pub-id><pub-id pub-id-type="medline">33330087</pub-id></nlm-citation></ref><ref id="ref41"><label>41</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>L</given-names> </name><name name-style="western"><surname>Zou</surname><given-names>X</given-names> </name><name name-style="western"><surname>Zou</surname><given-names>J</given-names> </name><name name-style="western"><surname>Zhang</surname><given-names>GA</given-names> </name></person-group><article-title>A review of recent research on the role of microRNAs in renal cancer</article-title><source>Med Sci Monit</source><year>2021</year><month>05</month><day>8</day><volume>27</volume><fpage>e930639</fpage><pub-id pub-id-type="doi">10.12659/MSM.930639</pub-id><pub-id pub-id-type="medline">33963171</pub-id></nlm-citation></ref><ref id="ref42"><label>42</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muglia</surname><given-names>VF</given-names> </name><name name-style="western"><surname>Prando</surname><given-names>A</given-names> </name></person-group><article-title>Renal cell carcinoma: histological classification and correlation with imaging findings</article-title><source>Radiol Bras</source><year>2015</year><volume>48</volume><issue>3</issue><fpage>166</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1590/0100-3984.2013.1927</pub-id><pub-id pub-id-type="medline">26185343</pub-id></nlm-citation></ref><ref id="ref43"><label>43</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Athanazio</surname><given-names>DA</given-names> </name><name name-style="western"><surname>Amorim</surname><given-names>LS</given-names> </name><name name-style="western"><surname>da Cunha</surname><given-names>IW</given-names> </name><etal/></person-group><article-title>Classification of renal cell tumors &#x2013; current concepts and use of ancillary tests: recommendations of the Brazilian Society of Pathology</article-title><source>Surg Exp Pathol</source><year>2021</year><month>12</month><volume>4</volume><issue>1</issue><fpage>4</fpage><pub-id pub-id-type="doi">10.1186/s42047-020-00084-x</pub-id></nlm-citation></ref><ref id="ref44"><label>44</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanguedolce</surname><given-names>F</given-names> </name><name name-style="western"><surname>Mazzucchelli</surname><given-names>R</given-names> </name><name name-style="western"><surname>Falagario</surname><given-names>UG</given-names> </name><etal/></person-group><article-title>Diagnostic biomarkers in renal cell tumors according to the latest WHO classification: a focus on selected new entities</article-title><source>Cancers (Basel)</source><year>2024</year><month>05</month><day>13</day><volume>16</volume><issue>10</issue><fpage>1856</fpage><pub-id pub-id-type="doi">10.3390/cancers16101856</pub-id><pub-id pub-id-type="medline">38791935</pub-id></nlm-citation></ref><ref id="ref45"><label>45</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lam</surname><given-names>JS</given-names> </name><name name-style="western"><surname>Shvarts</surname><given-names>O</given-names> </name><name name-style="western"><surname>Leppert</surname><given-names>JT</given-names> </name><name name-style="western"><surname>Pantuck</surname><given-names>AJ</given-names> </name><name name-style="western"><surname>Figlin</surname><given-names>RA</given-names> </name><name name-style="western"><surname>Belldegrun</surname><given-names>AS</given-names> </name></person-group><article-title>Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system</article-title><source>J Urol</source><year>2005</year><month>08</month><volume>174</volume><issue>2</issue><fpage>466</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1097/01.ju.0000165572.38887.da</pub-id><pub-id pub-id-type="medline">16006866</pub-id></nlm-citation></ref><ref id="ref46"><label>46</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Potti</surname><given-names>A</given-names> </name><name name-style="western"><surname>George</surname><given-names>DJ</given-names> </name></person-group><article-title>Tyrosine kinase inhibitors in renal cell carcinoma</article-title><source>Clin Cancer Res</source><year>2004</year><month>09</month><day>15</day><volume>10</volume><issue>18 Pt 2</issue><fpage>6371S</fpage><lpage>6S</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-050014</pub-id><pub-id pub-id-type="medline">15448033</pub-id></nlm-citation></ref><ref id="ref47"><label>47</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sch&#x00F6;ffski</surname><given-names>P</given-names> </name><name name-style="western"><surname>Dumez</surname><given-names>H</given-names> </name><name name-style="western"><surname>Clement</surname><given-names>P</given-names> </name><etal/></person-group><article-title>Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review</article-title><source>Ann Oncol</source><year>2006</year><month>08</month><volume>17</volume><issue>8</issue><fpage>1185</fpage><lpage>1196</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdj133</pub-id><pub-id pub-id-type="medline">16418310</pub-id></nlm-citation></ref><ref id="ref48"><label>48</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>W</given-names> </name><name name-style="western"><surname>Atkins</surname><given-names>MB</given-names> </name><name name-style="western"><surname>McDermott</surname><given-names>DF</given-names> </name></person-group><article-title>Checkpoint inhibitor immunotherapy in kidney cancer</article-title><source>Nat Rev Urol</source><year>2020</year><month>03</month><volume>17</volume><issue>3</issue><fpage>137</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1038/s41585-020-0282-3</pub-id><pub-id pub-id-type="medline">32020040</pub-id></nlm-citation></ref><ref id="ref49"><label>49</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rassy</surname><given-names>E</given-names> </name><name name-style="western"><surname>Flippot</surname><given-names>R</given-names> </name><name name-style="western"><surname>Albiges</surname><given-names>L</given-names> </name></person-group><article-title>Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma</article-title><source>Ther Adv Med Oncol</source><year>2020</year><volume>12</volume><fpage>1758835920907504</fpage><pub-id pub-id-type="doi">10.1177/1758835920907504</pub-id><pub-id pub-id-type="medline">32215057</pub-id></nlm-citation></ref><ref id="ref50"><label>50</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braun</surname><given-names>DA</given-names> </name><name name-style="western"><surname>Bakouny</surname><given-names>Z</given-names> </name><name name-style="western"><surname>Hirsch</surname><given-names>L</given-names> </name><etal/></person-group><article-title>Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma</article-title><source>Nat Rev Clin Oncol</source><year>2021</year><month>04</month><volume>18</volume><issue>4</issue><fpage>199</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1038/s41571-020-00455-z</pub-id><pub-id pub-id-type="medline">33437048</pub-id></nlm-citation></ref><ref id="ref51"><label>51</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ravaud</surname><given-names>A</given-names> </name></person-group><article-title>Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies</article-title><source>Oncologist</source><year>2011</year><volume>16 Suppl 2</volume><issue>Suppl 2</issue><fpage>32</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2011-S2-32</pub-id><pub-id pub-id-type="medline">21346038</pub-id></nlm-citation></ref><ref id="ref52"><label>52</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamli</surname><given-names>H</given-names> </name><name name-style="western"><surname>Li</surname><given-names>L</given-names> </name><name name-style="western"><surname>Gobe</surname><given-names>GC</given-names> </name></person-group><article-title>Limitations to the therapeutic potential of tyrosine kinase inhibitors and alternative therapies for kidney cancer</article-title><source>Ochsner J</source><year>2019</year><volume>19</volume><issue>2</issue><fpage>138</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.31486/toj.18.0015</pub-id><pub-id pub-id-type="medline">31258426</pub-id></nlm-citation></ref><ref id="ref53"><label>53</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Espi</surname><given-names>M</given-names> </name><name name-style="western"><surname>Teuma</surname><given-names>C</given-names> </name><name name-style="western"><surname>Novel-Catin</surname><given-names>E</given-names> </name><etal/></person-group><article-title>Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study</article-title><source>Eur J Cancer</source><year>2021</year><month>04</month><volume>147</volume><fpage>29</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2021.01.005</pub-id><pub-id pub-id-type="medline">33607383</pub-id></nlm-citation></ref><ref id="ref54"><label>54</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barrueto</surname><given-names>L</given-names> </name><name name-style="western"><surname>Caminero</surname><given-names>F</given-names> </name><name name-style="western"><surname>Cash</surname><given-names>L</given-names> </name><name name-style="western"><surname>Makris</surname><given-names>C</given-names> </name><name name-style="western"><surname>Lamichhane</surname><given-names>P</given-names> </name><name name-style="western"><surname>Deshmukh</surname><given-names>RR</given-names> </name></person-group><article-title>Resistance to checkpoint inhibition in cancer immunotherapy</article-title><source>Transl Oncol</source><year>2020</year><month>03</month><volume>13</volume><issue>3</issue><fpage>100738</fpage><pub-id pub-id-type="doi">10.1016/j.tranon.2019.12.010</pub-id><pub-id pub-id-type="medline">32114384</pub-id></nlm-citation></ref><ref id="ref55"><label>55</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sato</surname><given-names>K</given-names> </name><name name-style="western"><surname>Tsuchiya</surname><given-names>N</given-names> </name><name name-style="western"><surname>Sasaki</surname><given-names>R</given-names> </name><etal/></person-group><article-title>Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma</article-title><source>Jpn J Cancer Res</source><year>1999</year><month>08</month><volume>90</volume><issue>8</issue><fpage>874</fpage><lpage>879</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.1999.tb00829.x</pub-id><pub-id pub-id-type="medline">10543260</pub-id></nlm-citation></ref><ref id="ref56"><label>56</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schips</surname><given-names>L</given-names> </name><name name-style="western"><surname>Dalpiaz</surname><given-names>O</given-names> </name><name name-style="western"><surname>Lipsky</surname><given-names>K</given-names> </name><etal/></person-group><article-title>Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group</article-title><source>Eur Urol</source><year>2007</year><month>01</month><volume>51</volume><issue>1</issue><fpage>168</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2006.06.026</pub-id><pub-id pub-id-type="medline">16844285</pub-id></nlm-citation></ref><ref id="ref57"><label>57</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beuselinck</surname><given-names>B</given-names> </name><name name-style="western"><surname>Vano</surname><given-names>YA</given-names> </name><name name-style="western"><surname>Oudard</surname><given-names>S</given-names> </name><etal/></person-group><article-title>Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib</article-title><source>BJU Int</source><year>2014</year><month>07</month><volume>114</volume><issue>1</issue><fpage>81</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1111/bju.12494</pub-id><pub-id pub-id-type="medline">24215209</pub-id></nlm-citation></ref><ref id="ref58"><label>58</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pantuck</surname><given-names>AJ</given-names> </name><name name-style="western"><surname>Zeng</surname><given-names>G</given-names> </name><name name-style="western"><surname>Belldegrun</surname><given-names>AS</given-names> </name><name name-style="western"><surname>Figlin</surname><given-names>RA</given-names> </name></person-group><article-title>Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway</article-title><source>Clin Cancer Res</source><year>2003</year><month>10</month><day>15</day><volume>9</volume><issue>13</issue><fpage>4641</fpage><lpage>4652</lpage><pub-id pub-id-type="medline">14581333</pub-id></nlm-citation></ref><ref id="ref59"><label>59</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>L</given-names> </name><name name-style="western"><surname>Qiu</surname><given-names>Y</given-names> </name><name name-style="western"><surname>Tong</surname><given-names>X</given-names> </name></person-group><article-title>Ferroptosis in renal cancer therapy: a narrative review of drug candidates</article-title><source>Cancers (Basel)</source><year>2024</year><month>09</month><day>11</day><volume>16</volume><issue>18</issue><fpage>3131</fpage><pub-id pub-id-type="doi">10.3390/cancers16183131</pub-id><pub-id pub-id-type="medline">39335103</pub-id></nlm-citation></ref><ref id="ref60"><label>60</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kruk</surname><given-names>L</given-names> </name><name name-style="western"><surname>Mamtimin</surname><given-names>M</given-names> </name><name name-style="western"><surname>Braun</surname><given-names>A</given-names> </name><etal/></person-group><article-title>Inflammatory networks in renal cell carcinoma</article-title><source>Cancers (Basel)</source><year>2023</year><month>04</month><day>9</day><volume>15</volume><issue>8</issue><fpage>2212</fpage><pub-id pub-id-type="doi">10.3390/cancers15082212</pub-id><pub-id pub-id-type="medline">37190141</pub-id></nlm-citation></ref><ref id="ref61"><label>61</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>JW</given-names> </name><name name-style="western"><surname>Wan</surname><given-names>S</given-names> </name><name name-style="western"><surname>Li</surname><given-names>KP</given-names> </name><name name-style="western"><surname>Chen</surname><given-names>SY</given-names> </name><name name-style="western"><surname>Yang</surname><given-names>L</given-names> </name></person-group><article-title>Gut and urinary microbiota: the causes and potential treatment measures of renal cell carcinoma</article-title><source>Front Immunol</source><year>2023</year><volume>14</volume><fpage>1188520</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1188520</pub-id><pub-id pub-id-type="medline">37441065</pub-id></nlm-citation></ref><ref id="ref62"><label>62</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>M</given-names> </name><name name-style="western"><surname>Shariat</surname><given-names>SF</given-names> </name><name name-style="western"><surname>Cheng</surname><given-names>C</given-names> </name><etal/></person-group><article-title>Prognostic factors and predictive models in renal cell carcinoma: a contemporary review</article-title><source>Eur Urol</source><year>2011</year><month>10</month><volume>60</volume><issue>4</issue><fpage>644</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2011.06.041</pub-id><pub-id pub-id-type="medline">21741163</pub-id></nlm-citation></ref><ref id="ref63"><label>63</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsieh</surname><given-names>JJ</given-names> </name><name name-style="western"><surname>Le</surname><given-names>V</given-names> </name><name name-style="western"><surname>Cao</surname><given-names>D</given-names> </name><name name-style="western"><surname>Cheng</surname><given-names>EH</given-names> </name><name name-style="western"><surname>Creighton</surname><given-names>CJ</given-names> </name></person-group><article-title>Genomic classifications of renal cell carcinoma: a critical step towards the future application of personalized kidney cancer care with pan-omics precision</article-title><source>J Pathol</source><year>2018</year><month>04</month><volume>244</volume><issue>5</issue><fpage>525</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1002/path.5022</pub-id><pub-id pub-id-type="medline">29266437</pub-id></nlm-citation></ref><ref id="ref64"><label>64</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knudsen</surname><given-names>JE</given-names> </name><name name-style="western"><surname>Rich</surname><given-names>JM</given-names> </name><name name-style="western"><surname>Ma</surname><given-names>R</given-names> </name></person-group><article-title>Artificial intelligence in pathomics and genomics of renal cell carcinoma</article-title><source>Urol Clin North Am</source><year>2024</year><month>02</month><volume>51</volume><issue>1</issue><fpage>47</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.ucl.2023.06.002</pub-id><pub-id pub-id-type="medline">37945102</pub-id></nlm-citation></ref><ref id="ref65"><label>65</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papadia</surname><given-names>G</given-names> </name><name name-style="western"><surname>Pacella</surname><given-names>M</given-names> </name><name name-style="western"><surname>Perrone</surname><given-names>M</given-names> </name><name name-style="western"><surname>Giliberti</surname><given-names>V</given-names> </name></person-group><article-title>A comparison of different topic modeling methods through a real case study of Italian customer care</article-title><source>Algorithms</source><year>2023</year><volume>16</volume><issue>2</issue><fpage>94</fpage><pub-id pub-id-type="doi">10.3390/a16020094</pub-id></nlm-citation></ref></ref-list><app-group><supplementary-material id="app1"><label>Checklist 1</label><p>Bibliometric analysis checklist.</p><media xlink:href="cancer_v12i1e78797_app1.pdf" xlink:title="PDF File, 97 KB"/></supplementary-material></app-group></back></article>